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Abstract
‘Covert’ cerebral small vessel disease (ccSVD) is common on neuroimaging in persons without overt neurological
manifestations, and increases the risk of future stroke, cognitive impairment, dependency, and death. These European
Stroke Organisation (ESO) guidelines provide evidence-based recommendations to assist with clinical decisions about
management of ccSVD, specifically white matter hyperintensities and lacunes, to prevent adverse clinical outcomes. The
guidelines were developed according to ESO standard operating procedures and Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE) methodology. We prioritised the clinical outcomes of stroke,
cognitive decline or dementia, dependency, death, mobility and mood disorders, and interventions of blood pressure
lowering, antiplatelet drugs, lipid lowering, lifestyle modifications, glucose lowering and conventional treatments for
dementia. We systematically reviewed the literature, assessed the evidence, formulated evidence-based recommenda-
tions where feasible, and expert consensus statements. We found little direct evidence, mostly of low quality. We
recommend patients with ccSVD and hypertension to have their blood pressure well controlled; lower blood pressure
targets may reduce ccSVD progression. We do not recommend antiplatelet drugs such as aspirin in ccSVD. We found
little evidence on lipid lowering in ccSVD. Smoking cessation is a health priority. We recommend regular exercise which
may benefit cognition, and a healthy diet, good sleep habits, avoiding obesity and stress for general health reasons. In
ccSVD, we found no evidence for glucose control in the absence of diabetes or for conventional Alzheimer dementia
treatments. Randomised controlled trials with clinical endpoints are a priority for ccSVD.
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Introduction
Cerebral small vessel disease (SVD) refers to the pres-
ence of brain lesions found on CT or MR brain imag-
ing or pathology examination, thought to have
resulted from disease of the small blood vessels that
perforate into the brain, primarily the white matter
and deep grey matter. The full spectrum includes
covert cerebral SVD (ccSVD) detected incidentally
on neuroimaging, and SVD-related clinical presenta-
tions with stroke, cognitive decline or dementia, mood
or physical dysfunction. The best described
pathological-anatomical cerebral lesions are white
matter hyperintensities (WMH), lacunes, microbleeds
and enlarged perivascular spaces.1
SVD is considered to cause 25% of ischaemic
strokes and most haemorrhagic strokes in older
patients. SVD is also the commonest cause of vascular
cognitive impairment and vascular dementia and is
common in mixed dementias with other dementia
pathologies, and is also a common cause of gait and
balance problems and mood disorders in older people.2
Individuals with SVD may therefore present to stroke
services, cognitive, movement disorder or neuropsychi-
atry clinics.3
However, findings suggesting SVD are also com-
monly found on CT or MRI brain imaging performed
for investigation of other disorders in persons with no
apparent neurological history, causing the lesions to be
referred to as ‘silent’ or ‘covert’ cerebral SVD, hence-
forth in this Guideline referred to as ccSVD. Therefore,
subjects with CT or MRI signs of ccSVD are often
encountered by general practitioners and at various
clinics. The number of persons with ccSVD lesions,
and the amount and extent of ccSVD lesions per indi-
vidual, increase with ageing,4,5 meaning that the
number or volume of lesions that could be considered
‘normal’ varies with age.4 These lesions usually extend
with time, although they may also recover.6,7 ccSVD is
important, since it increases the risk of future stroke,
dementia or death, both in persons with ccSVD lesions5
and in patients presenting with stroke of any type.8
Since increasing evidence indicates that the burden of
MRI-markers of cSVD is associated with risk of com-
plications at any age, and we do not know of any work
identifying ‘safe’ thresholds of SVD, we prefer not to
encourage use of ‘age norms’ at present.
We summarise here a few general comments which
are relevant to the concepts behind this Guideline. SVD,
with its covert, multiple clinical coincident expressions,
and numerous outcomes of importance, does not easily
lend itself to the conventional approaches required in
formulating clinical guidelines. The topic is massive, dif-
ficult to identify, and relevant information may be
buried in secondary publications or seemingly irrelevant
studies. This theme thus presents complexities and prac-
tical barriers. On the basis of this, in this first part of the
ESO ccSVD Guideline, our group reached a consensus
to focus on the following areas: ccSVD primarily
defined as WMH and lacunes (population, P); pharma-
cological interventions for stroke prevention (antihyper-
tensive, antiplatelet, lipid lowering), lifestyle
interventions for stroke or dementia prevention or
healthy ageing (smoking cessation, weight reduction,
dietary interventions, physical exercise, cognitive/social
interventions, sleep/CPAP, or a mixture of these), glu-
cose control, and conventional pharmacological anti-
Alzheimer dementia treatments (interventions, I). The
comparators are absence of the above intervention, or
‘best medical practice’, or less intense version of the
intervention e.g. single vs dual antiplatelet agents, or
target-based intervention such as blood pressure (BP)
<140mmHg versus <120mmHg (comparator, C);
and clinical outcomes are clinically apparent stroke,
dependency, death, major adverse cardiac events
(MACE), systemic adverse events like bleeding, cogni-
tive decline, dementia, mobility including falls, and
mood including depression (outcomes, O).
Although SVD lesion progression as observed on
neuroimaging is a commonly reported research out-
come of interest, our Group did not rate this highly
enough to be included as an outcome (O) in this clinical
guideline since robust clinical outcomes are of more
importance to clinical services and to patients.
However, in selected parts of this document, we com-
ment briefly on imaging lesion changes.
Monogenic forms of ccSVD were not included since
they were recently addressed in an EAN Guideline.9
Finally, a particular challenge was to define
‘ccSVD’. Increasing evidence indicates that SVD
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lesions are not ‘silent’ especially when present in larger
numbers involving more areas of the brain. In fact
patients with higher burdens of ccSVD lesions have
atypical neurological, neuropsychiatric and cognitive
symptoms (summarised in10) but these are poorly rec-
ognised in clinical practice and probably also by
patients, and therefore have not received much atten-
tion and have not, as yet, been used to identify relevant
patients in clinical trials. Furthermore, SVD affects
multiple cognitive domains including memory and
not just executive function as is commonly thought.11,12
At the present time, there is no formal clinical defini-
tion that distinguishes ccSVD which is truly silent from
symptom-associated ccSVD. Therefore our Guideline
Group adopted a pragmatic approach, focusing on
patients with no formal diagnosis of TIA/stroke, cog-
nitive impairment or dementia, mobility or mood dis-
orders. However we recognise that ccSVD lesions are
likely to be present in persons who are older, or have
major risk factors such as hypertension or diabetes,
even if their burden of SVD lesions has not been for-
mally assessed, and that some ccSVD patients may
have subtle undetected or unassessed changes in cogni-
tive performance, mood or mobility.
Methods
These guidelines were initiated by the ESO. A Module
Working Group (MWG) was established, consisting of
11 experts (JMW, Chair; AGL, co-Chair; HC, CC, SD,
F-EDL, FD, CE, HJ, LP, JS). The MWG was joined
by four fellows during study screening (RO, SE, SR,
SS) who assisted with abstract and full text screening
and drafting the text. The MWG included eight neu-
rologists, one neuropsychologist, one stroke physician,
one neuroradiologist, all experts in SVD with interests
in neuroepidemiology, cognitive testing, genetic, spo-
radic ischaemic and haemorrhagic SVDs. Fellows
were all either trainee neurologists or post-doctoral fel-
lows interested in stroke or early career epidemiolo-
gists. The composition of this group was approved by
the ESO Guidelines Board and the ESO Executive
Committee, based on a review of the intellectual and
financial disclosures of the proposed members.
The guidelines were developed using Grading of
Recommendations, Assessment, Development, and
Evaluation (GRADE) methodology13 and the ESO
Standard Operating Procedure,14 as described
previously.15
The MWG developed a list of topics, and corre-
sponding outcomes of clinical interest. The outcomes
were rated as critical, important, or of limited impor-
tance according to GRADE criteria.13,14
Selection of population, intervention,
comparator, and outcome
Interventions in ccSVD might include those used for
stroke or dementia primary or secondary prevention,
lifestyle changes, antidepressant and other interven-
tions and outcomes including worsening lesion
burden, stroke, dementia, mobility and mood, depen-
dency, major adverse cardiovascular events and death.
The MWG voted in a closed ballot to identify which
PICO questions were considered to be the highest pri-
ority. Considering the full range of clinical presenta-
tions in SVD and constructing the complete PICO
questions initially resulted in approximately 36 PICO
questions which were clearly unworkable with the time
and resources available. The MWG decided to priori-
tize this first ESO SVD Guideline on patients with
ccSVD in whom no guidelines are currently available,
above patients presenting with stroke, cognitive
decline, mobility or mood disorders whose manage-
ment is partly covered by broader guidelines on these
conditions. The MWG selected three stroke prevention
treatments (BP lowering, antiplatelet drugs, lipid low-
ering), lifestyle interventions (smoking cessation, exer-
cise, diet including vitamins, cognitive behavior
therapy), glucose lowering agents and anti-dementia
treatments as key Interventions for which the effect in
ccSVD was uncertain. The MWG prioritized the
absence or a lesser amount of the intervention as
Comparators (for example, BP or lipid or glucose low-
ering might be compared to less intense lowering of
these parameters or to avoiding the lowering interven-
tion altogether – both options were considered), and
chose clinical outcomes of stroke (ischaemic or hae-
morrhagic), cognitive decline or dementia, MACE,
death, dependency, loss of mobility, and mood disor-
ders as clinically important Outcomes. Non-clinical
outcomes such as blood biomarkers, WMH progres-
sion or silent infarcts were excluded from the PICO
questions for aforementioned reasons.
The MWG focused on WMH and lacunes as the
ccSVD lesions of interest. We did not examine two
other subtypes of ccSVD: microbleeds where there
are recent reviews and large studies16 or enlarged peri-
vascular spaces because their definition and clinical
importance are more unclear and studies still scarce.
The MWG formulated six main PICO (Population,
Intervention, Comparator, Outcome) questions each
with several sub-questions relating to the seven differ-
ent Outcomes of interest. These were subsequently
approved by the ESO Guidelines board and the ESO
Executive Committee.
For each PICO question, search terms were identified,
tested, refined and agreed by JMW and AGL with the
ESO Guidelines methodologist, Martin Taylor-Rowan
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(MT-R). Search terms are listed in the Supplementary
materials.
Identification and selection relevant
studies
MT-R then conducted systematic searches of the
PubMed, Embase, and Cochrane Library databases,
covering the period from the inception of each data-
base to 11th Dec 2020. The search strategy was
informed by terminology for SVD identified in other
SVD research1 and for each intervention and outcome.
Strategies were tested and modified to optimise sensi-
tivity and specificity before the final search was run.
The search results were loaded into the web-based plat-
form Covidence for assessment and consequent system-
atic review by the MWG.
Different combinations of two MWG authors inde-
pendently screened the titles and abstracts of publica-
tions registered in Covidence and assessed the full text
of potentially relevant studies. We focused on random-
ized controlled trials and systematic reviews of RCTs,
but also considered other types of study such as health
registry data analyses, large observational studies (min-
imum size 100 subjects) and systematic reviews or indi-
vidual patient data meta-analyses of observational
studies since we anticipated a lack of high quality
RCTs. We noted potentially relevant ongoing studies
for future reference. All disagreements were resolved by
discussion between the two authors or by a third MWG
author. We also searched reference lists of review
articles, the authors own reference libraries, and previ-
ous guidelines for additional relevant material.
For each question, a group of three or four MWG
members assisted by one or more Fellows (a ‘PICO
group’, details see author contributions) was formed
to evaluate the available evidence. The risk of selection,
performance, detection, attrition and reporting biases
in each randomised trial was assessed using the
Cochrane Collaboration’s tool,17 and heterogeneity
across studies was assessed using Cochran’s Q
(reported as a p value) and I2 statistics.18
For each PICO question and each outcome, the
quality of evidence was rated using the GRADEpro
Guideline Development Tool (McMaster University,
2015; developed by Evidence Prime, Inc.) using guide-
lines for non-pooled data as necessary,19 as high, mod-
erate, low or very low14 by MT-R and agreed by at
least two members of each PICO group.
The relevant PICO group analysed the available pri-
mary and any additional data, prepared tables and fig-
ures, and drafted three sections of text: ‘analysis of
current evidence’ which focused on relevant RCTs
and/or systematic reviews; ‘additional information’ to
summarise indirect evidence and provide context about
the Intervention of interest in ccSVD or related presen-
tations; and ‘expert consensus statement’ if the PICO
group considered that not enough evidence was avail-
able to provide an evidence-based recommendation for
situations in which practical guidance is often needed in
everyday clinical practice. Since there were few RCTs
with clinical outcomes, where reasonable, we also
describe effects of the Intervention of interest on
WMH change and performed a meta-analysis where fea-
sible using weighted random effects meta-analysis (rela-
tive weights for each study are based on relative sample
size) on the standard mean difference of SVD change
between the intervention vs control groups using
’Comprehensive Meta-analysis’ software (Version 3,
Borenstein M., Biostat, Englewood, NJ 2013). We
assessed heterogeneity using the I2 statistic. This was
possible for BP lowering and lipid lowering
Interventions.
Each PICO Group formulated an evidence-based
recommendation according to the GRADE evidence
profiles and the ESO standard operating procedure.14
The Expert Consensus Statements are based on
voting by all expert MWG members. Importantly,
these Expert Consensus Statements should not be
regarded as evidence-based recommendations, since
they only reflect the opinion of the MWG.
The Guidelines document was reviewed several
times by all MWG members, and modified using a
Delphi approach until consensus was reached. The doc-
ument was subsequently reviewed and approved by two
external reviewers, members of the ESO Guidelines
Board and Executive Committee, and the Editor of
the European Stroke Journal.
Results
PICO 1: In patients with covert cerebral small vessel
diseases [WMH and/or lacunes], does antihypertensive
treatment, compared to less intense or avoiding this
intervention, reduce ischaemic or haemorrhagic strokes
(1.1), cognitive decline or dementia (1.2), dependency
(1.3), death (1.4), MACE (1.5), mobility (1.6), or mood
disorders (1.7).
Analysis of current evidence
The literature search identified three trials addressing
this PICO question (Figure 1).20–22 All three studies
had a high risk of bias and suffered from imprecision
due to very small sample size, as well as indirectness,
due either to no control group for comparison,22 or the
control group also being given intervention.20,21
Pooling of these trials was not possible, therefore we
describe each and the outcomes that are addressed.
CXIV European Stroke Journal 6(2)
Table 1 summarizes the findings for all PICO1 trials
and Table 2 the quality of the results.
The most relevant of these for PICO1 is the
INFINITY prospective, randomized, open-label,
blinded end points trial.20 This study included 199
patients aged 75 years (mean age 80.5 years) with sys-
tolic hypertension (systolic BP [SBP] of 150 to
170mmHg if taking 1 antihypertensive drugs or
>170mmHg on 0 to 1 antihypertensive drug at screen-
ing) and MRI evidence of WMH (0.5% lesion volume
corrected for intracranial cavity volume size, mean
WMH volume at baseline 20.6 mL). Patients were ran-
domized to receive intensive treatment targeting a 24-
hour mean SBP of 130mmHg, versus standard treat-
ment targeting145mmHg with antihypertensive ther-
apies. Primary outcomes were changes in mobility (gait
speed) and accrual of WMH volume after three years.
Secondary outcomes included changes in cognitive func-
tion and adverse events. The mean 24-hour SBP was
127.7mmHg in the intensive treatment group and
144.0mmHg in the standard treatment group. Over
three years, the risk of stroke, cognitive outcomes, mor-
tality, and changes in gait speed (PICOs 1.1, 1.2, 1.4,
1.6), did not differ significantly between treatment
groups. Major non-fatal adverse cardiovascular events
(PICO 1.5) were less common in the intensive vs. stan-
dard treatment group (P<0.01).
The study population of the two other trials did not
strictly match our definition of ccSVD. In a prelimi-
nary open trial,22 Pantoni et al. enrolled 31 patients
with dementia (DSM-IIIR), leukoaraiosis on the CT
scan with a Hachinski ischaemic score >7,23 and
global deterioration on the Global Deterioration
Scale24 and the Sandoz Clinical Assessment Geriatric
Scale.25 These patients were administered for 1 year a
90 mg daily dose of Nimodipine, a calcium channel
blocker used primarily for its vasodilating properties
on brain vessels, and not as an antihypertensive drug.
Primary and secondary outcomes are not clearly distin-
guished. During follow-up a significant improvement
Figure 1. Search results PICO 1.










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































was observed in the Hamilton depression rating scale
and the Corsi bock tapping test, while no difference
was observed for other cognitive tests or for the
Akhtar Disability rating scale score (PICOs 1.2, 1.3,
1.7). The randomized, double-blinded and placebo-
controlled clinical trial by Zhang et al.21 included
732 hypertensive patients (SBP 140mmHg and/or
diastolic BP (DBP) 90mmHg, or self- reported use
of BP-lowering medications in the last 2 weeks), aged
60 years and taking hydrochlorothiazide as their
baseline medication. These were randomized using a
2 2 factorial design with antihypertensive (telmisar-
tan vs. placebo) and lipid-modulating (low-dose rosu-
vastatin vs. placebo) arms. Participants were not
specifically selected for having ccSVD, but all under-
went a brain MRI, showing a mean WMH volume at
baseline of 5.3 mL (10.4% had a WMH Fazekas score
21). Results by WMH severity were not provided.
The decline over time in mini mental state examination
(MMSE) and Dementia Rating Scale (DRS) scores did
not differ significantly between the telmisartan and
placebo groups, nor did the incidence of cognitive
impairment, which was defined by a MMSE 23 at
any annual follow-up visit or a decline by 3 points
between any two annual follow-up visits, and/or a
DRS score 123 at any annual follow-up visit
(PICO 1.2).
Additional information
Given the dearth of direct evidence, we also reviewed
indirect evidence for PICO1. Studies evaluating the
impact of antihypertensive treatment on some PICO1
outcomes (stroke, MACE, mortality, dementia) outside
the context of SVD are numerous, while little to no
data is available on the impact of antihypertensive
treatment on other PICO1 outcomes (mobility, mood
disorders).
Hypertension is the strongest acquired risk factor
for stroke (PICO 1.1) and, because of its high frequen-
cy, about half of all strokes are attributable to hyper-
tension.26 Many clinical trials and meta-analyses have
long demonstrated that lowering BP reduces the risk
of stroke, coronary heart disease events (in primary
and in secondary prevention), and the risk of
death.27,28 The SPRINT trial showed that among
9361 patients aged 50 years (mean 67.9), with an
SBP between 130 and 180mmHg, and at high risk
for cardiovascular events but without diabetes or a
history of stroke, targeting an SBP <120mmHg, as
compared with <140mmHg, resulted in lower rates of
fatal and nonfatal major cardiovascular events and
death from any cause, although significantly higher
rates of some adverse events were observed in the










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































participants aged 75 years, targeting an SBP
<120mmHg compared with an SBP <140mmHg
also resulted in significantly lower rates of fatal and
nonfatal MACE and death from any cause.30 Based
on this and other evidence, some but not all clinical
guidelines in recent years have recommended BP tar-
gets lower than the standard targets of less than 140/
90mmHg.31,32 Indeed, there remains some controversy
on the risk/benefit ratio of very low SBP targets.33 The
earlier ACCORD trial for instance, in 4733 partici-
pants with type 2 diabetes at high vascular risk, had
not found any significant difference in the primary out-
come of nonfatal myocardial infarction, nonfatal
stroke, or death from cardiovascular causes in the
intensive (SBP <120mmHg) vs. the standard (SBP
<140mmHg) BP lowering group (although the risk
of stroke, a secondary outcome, was significantly
reduced), while the risk of adverse events was signifi-
cantly higher.34
The association of hypertension and antihypertensive
drugs with dementia (PICO 1.2) has long been contro-
versial. Early systematic reviews suggested that the asso-
ciation of BP with cognitive decline and dementia is
complex and differs according to age and follow-up dura-
tion.35 Overall, the relationship was stronger in studies
with a longer follow-up and with BP measurements in
midlife;36,37 while studies with a short follow-up or
cross-sectional studies in late-life were less consistent,
with no association or even hypertension being associat-
ed with a lower risk of dementia.38 While exposure to
hypertension in midlife probably better reflects the total
exposure to elevated BP throughout the life course, stud-
ies in late-life are also exposed to: (i) reverse causation
with BP drops induced by concomitant chronic diseases,
including neurodegenerative diseases; (ii) selective surviv-
al due to early death from vascular disease of individuals
exposed to high BP levels.39 The most recent systematic
review and meta-analysis of observational data on the
association of BP with cognitive impairment and demen-
tia (209 prospective studies), showed that midlife hyper-
tension is associated with 1.19 to 1.55 times increased risk
of cognitive disorders, starting at >130mmHg SBP on a
dose-response analysis.40 In late life, high SBP, lowDBP,
increased BP variability and orthostatic hypotension
were all associated with increased dementia risk,
although encouragingly, use of antihypertensive drugs
was associated with a 21% reduction in dementia
risk.40 This provides clear evidence that relationships
between BP and cognitive disorders are both age- and
BP type-dependent, suggesting that caution is still
needed until more data are available for older patients.
The most recent and largest Individual Participant
Data (IPD) meta-analysis, with the longest follow-up,
combined 6 population-based longitudinal cohort
studies (n¼31090, age >55 years, 7 to 22 years
follow-up).41 This study found that in participants in
the highest BP stratum (140/90mmHg) using any
versus no antihypertensive drug was associated with a
lower risk of dementia (HR 0.88, 0.79–0.98, p¼0.019)
and any dementia, with no difference between drug
classes. No significant effect of antihypertensives on
dementia was observed in participants in the normal
BP stratum (<140/90mmHg).41 A systematic review
of 27 longitudinal studies (21 observational, 6 RCTs,
n¼56866), found no clear evidence of dementia reduc-
tion for any antihypertensive drug versus placebo in
participants aged> 65 years, nor any evidence for a
drug class being superior to others, except for inconsis-
tent evidence of benefit for diuretics (across follow-up
time, comparator group, and outcome).42
Randomized trials of antihypertensive drugs that
have included an evaluation of dementia or cognitive
function (PICO 1.2), always as a secondary outcome,
also reported contrasted results, usually with a short
follow-up period compared with the slow pathophysi-
ological processes leading to dementia.43 In the
SPRINT-MIND trial (N¼9361), although intensive
BP lowering (SBP<120mmHg vs <140mmHg) did
not result in a significant reduction in the risk of prob-
able dementia for non-diabetic participants at high vas-
cular risk, a lower risk of the secondary combined
outcome of mild cognitive impairment or dementia
was observed (median follow-up 5.11 years).44 Of
note, the ACCORD-MIND trial (N¼4733), which
used a similar BP target (SBP<120mmHg) in diabetic
patients, observed a greater decline in total brain
volume (p¼0.01) but no difference in cognitive decline
compared with the standard BP intervention group at
40 and 80 months.45,46 In the largest systematic review
and meta-analysis combining 14 RCTs (96158 partici-
pants),47 BP lowering with antihypertensive agents
versus controls reduced the risk of dementia or cogni-
tive impairment (12 trials; 92135 participants; mean age
69 years, mean follow-up 4.1 years; odds ratio [OR],
0.93 [95% CI, 0.88–0.98]; absolute risk reduction,
0.39% [0.09%-0.68%]; I2¼ 0.0%) and slowed down
cognitive decline (8 trials; 67476 participants; 20.2%
vs 21.1% of participants over a mean trial follow-up
of 4.1 years; OR, 0.93 [0.88–0.99]; absolute risk reduc-
tion, 0.71% [0.19%-1.2%]; I2¼ 36.1%).47
In the absence of robust specific evidence on the clin-
ical impact of antihypertensive treatment in patients
with ccSVD, we examined the potential generalizability
of the aforementioned observations in broader aging
populations to patients with ccSVD. High BP (SBP
and DBP), as well as BP variability,48 have been consis-
tently and strongly associated with WMH burden and
WMH progression, as well as with the presence of
lacunes in several population-based studies, with evi-
dence for causality from Mendelian randomization
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analyses.49,50 Moreover, several trials have examined
the impact of antihypertensive treatment onWMH pro-
gression (either as a primary outcome,20,21 or, in most
instances, as a secondary outcome in a subset of the trial
participants46,51–55) and have been combined in two sys-
tematic reviews and meta-analyses.56,57 The latest, larg-
est systematic review57 combined seven trials on 2693
participants, with a mean follow-up duration between
24 and 60 months.20,21,51–55 Overall, compared with the
control group, patients in the (intensive) BP manage-
ment group had a slower progression of WMH, with a
pooled intergroup standard mean difference (SMD) for
WMH change of 0.22 (95% CI: 0.35, 0.09,
I2¼ 63%). For three studies comparing intensive vs.
standard BP targets (SPRINT-MIND, ACCORD-
MIND, INFINITY),20,54,55 the pooled SMD was
0.37 (95% CI:-0.50, -0.24, I2¼ 0%), while the
pooled SMD of studies comparing active antihyperten-
sive medication vs placebo (PROGRESS, PROFESS,
SCOPE, Zhang et al)21,51–53 was only 0.08 (95% CI:
0.17, 0.01, I2¼ 0%) and non-significant. Meta-regres-
sion analyses showed that the reduction in WMH pro-
gression was proportional to the magnitude of intensive
BP control (b¼0.028, P <0.001), while the mean age
of the study population and the duration of follow-up
were not associated with the effect measures. As our
guideline focuses on ccSVD, we conducted a new
meta-analysis excluding the two trials on stroke patients
(PROGRESS and PROFESS),52,53 seeking additional
data from study authors where necessary (Figure 2).
The main characteristics of the five trials included in
this meta-analysis are described in Table 3. Overall,
compared with the control group, patients in the
(intensive) BP management group had a slower progres-
sion of WMH, with a pooled intergroup SMD for
WMH change of 0.26 (95% CI: 0.45, 0.07,
I2¼ 72%). For the three studies comparing intensive
vs. standard BP targets (SPRINT-MIND, ACCORD-
MIND, INFINITY),20,54,55 the pooled SMD was iden-
tical to the last published meta-analysis by Lai et al.,57
while the pooled SMD of studies comparing active anti-
hypertensive medication vs placebo (SCOPE, Zhang et
al).21,51 was only 0.03 (95% CI: 0.17, 0.11, I2¼ 0%)
and non-significant. Table 3 also reports baseline and
absolute change values for BP and WMH volume.
Meta-regression analyses did not show any significant
modifying effect of baseline WMH volume (in all study
participants, p¼0.84) or of absolute change in WMH
volume over follow-up (in controls, p¼0.64) on the
association between (intensive) BP lowering and
WMH progression. Of note, these meta-regressions
should be interpreted with caution, given (i) the small
number of trials included; (ii) the fact that WMH
volume likely has a skewed distribution.
Overall, there is evidence indicating that antihyper-
tensive medication slows the progression of ccSVD,
especially intensive BP lowering. Given the strong
causal association of WMH burden with stroke and
dementia risk,5,49 and the high prevalence of WMH
in the population with increasing age, one can specu-
late that the impact of antihypertensive medication on
stroke and dementia risk may at least partly be medi-
ated by its impact on ccSVD. The INFINITY trial
(N¼199), currently the only RCT focusing specifically
on ccSVD patients, observed significantly smaller
changes in WMH volume over three years in the
Figure 2. Meta-analysis of effects of BP lowering in RCTs on WMH progression. Blue: ccSVD and hypertensive study population;
Red: Diabetic study population; Green: Hypertensive and/or high vascular risk study population; WMH: white matter hyperintensity.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Wardlaw et al. CXXI
intensive antihypertensive treatment compared with the
standard treatment group (0.29% vs. 0.48%; P¼0.03),
for a starting volume of 21.1 and 20.2 ml (more WMH
than most other studies, Table 3).
Additional studies focussed on ccSVD patients, on
larger samples, with a range of ccSVD burden and char-
acteristics, and longer follow-up periods, are warranted
to assess more precisely the impact of antihypertensive
medication both on ccSVD progression and clinical
outcomes. Of note, ongoing trials include: the
LEOPOLD trial (NCT02472028), comparing intensive
BP lowering (SBP<135mmHg) to routine BP manage-
ment in 820 older ccSVD patients with hypertension
and memory complaints (MMSE>20), with WMH pro-
gression over 3 years as a primary outcome and second-
ary clinical endpoints including stroke, cognitive decline,
dementia, gait, MACE, and mortality; the CEREBRAL
trial58 compares the impact of angiotensin-converting
enzyme inhibitors and angiotensin II receptor blockers
on fatal or non-fatal cerebrovascular events and progres-
sion of cerebrovascular lesions in 346 hypertensive
patients aged 65 years, with any cerebral ischaemic
lesion (overt or covert); trials testing the impact of BP
lowering drugs on microvascular function and on cere-
bral autoregulation capacity (NCT03082014; http://
www.who.int/trialsearch, NTR6661).
Regarding the following Evidence-based
Recommendation, please note that according to the
GRADE methodology, the QoE of these recommenda-
tions is very low for all outcomes since it is based on a
small number of small trials with a high risk of bias,
imprecision due to very small sample size, as well as
indirectness, due either to no control group for compar-
ison or the control group also being given intervention.
However, this is counterbalanced by the strength of
the additional information in support of:
(i) a benefit of antihypertensive treatment in hyperten-
sive patients in the population (many of whom are
expected to have ccSVD) to reduce the risk of
stroke, cardiovascular events (and possibly, with
weaker, recent evidence, also of dementia or cog-
nitive impairment); and
(ii) a benefit of antihypertensive treatment to slow
down the progression of ccSVD.
Evidence-based Recommendation
We recommend the use of antihypertensive treatment in
hypertensive ccSVD patients (140/90mmHg), to prevent
the extension of SVD lesions and related clinical
manifestations.
Quality of evidence: Very low
Strength of recommendation: Strong for intervention ""
Rationale for expert consensus statement
Additional studies are warranted in patients with ccSVD
to determine the ideal BP level below which extension of
SVD lesions and related clinical manifestations are best
prevented, and whether specific antihypertensive treat-
ments should be preferred over others, as there is cur-
rently no evidence for that. In the meantime, we do not
suggest a specific target BP in patients with ccSVD and
hypertension, but rather that BP is well controlled
according to standard targets set in local practice guide-
lines. As reduced cerebral blood flow and impaired cere-
bral autoregulation has been demonstrated in ccSVD
patients, there have been some concerns that in patients
with extensive ccSVD, very intensive BP lowering could
decrease perfusion, thus further increasing ischaemic
damage.59 The PRESERVE trial in 111 patients with
lacunar stroke, confluent WMH and hypertension does
not support this hypothesis, as intensive SBP lowering
(<125mmHg) was not associated with reduced cerebral
blood flow (substudy, N¼62) or with increase in white
matter damage assessed by diffusion tensor imaging
MRI.60–62 It is also reassuring that in the INFINITY
trial the rates of serious falls and syncope were compa-
rable between the treatment groups, suggesting that a
target mean 24-hour ambulatory SBP of 130mmHg is
safe in older individuals with hypertension. However,
additional studies are needed on larger groups of
ccSVD patients, with clinical endpoints including vascu-
lar events, cognition, mobility and mood, and taking
into account the effect of antihypertensive medication
on the different BP traits (SBP, DBP, BP variability,
orthostatic hypotension). Outside the specific context
of ccSVD, evidence from a recent Cochrane systematic
review, which included six RCTs (9484 participants), did
not support lower BP targets (<135/85mmHg) as com-
pared to standard BP targets (<140-160/90-100mmHg)
in people with hypertension and established cardiovas-
cular disease(myocardial infarction, stroke).31 This sys-
tematic review suggested that, in addition to a lack of
benefit for the lower BP target in terms of total or car-
diovascular mortality, total cardiovascular events, and
serious adverse events, a numerical increase in totalmor-
tality prompted caution. In the SPS3 trial, which focused
on 3020 patients with overt SVD (recent lacunar stroke),
although the use of an SBP target <130mmHg, com-
pared to a target of 130-149mmHg did not lead to a
significant reduction in all stroke, it was associated
with a significantly reduced rate of intracerebral hae-
morrhage (p¼0.03), and treatment-related serious
adverse events were infrequent.33
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Another unsolved question to explore in the future is
whether reducing BP ought to be recommended in all
patients with ccSVD, regardless of whether they have
clinically defined hypertension (>140/90mmHg), as is
a current practice in secondary stroke prevention since
the PROGRESS trial. In older populations a
non-negligible proportion of ccSVD is not caused by
hypertension, often related to cerebral amyloid angiop-
athy, although both mechanisms may co-exist and
interact.63 Recently a two-sample Mendelian randomi-
zation analysis suggested a causal association of
increasing BP with higher WMH volume even among
persons without clinically defined hypertension.49
Expert Consensus Statement
• All group members suggest that: BP should be appropri-
ately monitored and well controlled. Provided that BP is
well controlled we cannot advise any specific antihyper-
tensive treatment.
• Most group members suggest that: For ccSVD patients,
there is currently insufficient evidence to systematically
advocate targeting BP levels lower than standard tar-
gets, although more intensive BP lowering than conven-
tional BP lowering guidelines is associated with slower
progression of WMH burden.
• All group members suggest that: In ccSVD patients in
whom more intensive BP lowering targets are recom-
mended for other reasons there is no strong evidence
to suggest that this could be harmful.
• On current evidence the guideline group unanimously
does not support systematic BP lowering in normoten-
sive ccSVD patients.
PICO 2: In patients with covert cerebral small vessel
disease [WMH and/or lacunes], does antiplatelet treat-
ment, compared to less intense or avoiding this inter-
vention, reduce ischaemic or haemorrhagic strokes
(2.1), cognitive decline or dementia (2.2), dependency
(2.3), death (2.4), MACE (2.5), mobility (2.6), or mood
disorders (2.7)?
Analysis of current evidence
We identified one study in patients with ccSVD
(Figure 3, Table 4),64 and a second study in a popula-
tion that can be considered at high risk for ccSVD,
where antiplatelet therapy was trialled for preventing
the specified clinical outcomes defined in this guideline
document.64,65 Pooling was not possible, therefore we
describe each study and the PICO outcome that is
addressed.
Aspirin vs placebo
One randomised, double blind placebo-controlled trial
included patients 45 years with at least one silent
Figure 3. Search results PICO 2

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































brain infarct (SBI) but no previous clinical cerebrovas-
cular events for randomization to aspirin 100 mg
(n¼36) or placebo (n¼47).64 The primary endpoint
was the combined endpoint of ischaemic stroke, TIA,
and new silent brain infarcts (SBIs) detected at MRI
which had occurred in nine controls (19.1%) and two
subjects (5.6%) in the ASA group (p¼0.10) after four
years. A new stroke was observed in 2/47 (4.3%) sub-
jects in the control group and 1/36 (2.8%) in the ASA
group (OR: 0.64 (0.06–7.38), calculated based on indi-
vidual patient data in the publication) (PICO 2.1).
There were 1/47 (2.1%) deaths in the control group
and 0/36 (0%) deaths in the aspirin-treated group
(OR: 0.43 (0.02–10.73)); PICO 2.4). There were 1/47
(2.1%) myocardial infarctions in the control group and
2/36 (5.6%) in the aspirin-treated group (OR: 2.71
(0.24–31.08)); PICO 2.5). Findings should be inter-
preted with care as the number of incident ischaemic
strokes and myocardial infarctions were small with
wide confidence intervals including one. In addition,
there were important differences in prevalence of
hypertension between controls compared to aspirin
users (61.7% vs 47.2%, p¼0.188). The authors
reported no significant differences in secondary
endpoints.64
Cilostazol vs no antithrombotic treatment
Cilostazol has weak antiplatelet effects, in addition to
other actions. One trial randomized patients with Type
II diabetes (which can be considered a population at
high risk for SVD) to treatment with cilostazol 100-200
mg per day, n¼43 (34 with no brain lesions on baseline
MRI) or no antithrombotic treatment, n¼46, (27 with
no brain lesions on baseline MRI).65 After a study
period of 3.2 years, symptomatic brain infarcts
occurred in two subjects in the control group whereas
no stroke occurred in the cilostazol treatment group
(PICO 2.1). An increased number of infarct-like lesions
as detected by MRI at the end of the study was seen in
16 subjects in the control group and two in the cilosta-
zol group.65
The two identified studies64,65 are both small and
even though a tendency to better clinical outcomes
was seen in both studies, they provide insufficient sup-
port for a general recommendation of antiplatelet
treatment in subjects with ccSVD to avoid new clinical
events (Table 5), which only includes the study by
Maestrini et al64 because we did not consider the
study of patient with diabetes mellitus by Shinoda-
Tagawa et al65 to be a “true” primary prevention study.
We found no randomized trials of antiplatelet agents
in patients with ccSVD that provided evidence of
effects on the outcomes of cognitive decline or
dementia (PICO 2.2), dependency (PICO 2.3), mobility
(PICO 2.6) or mood disorders (PICO 2.7).
Additional information
There are several stroke secondary prevention studies
examining if antiplatelet treatment is beneficial for pre-
venting progress of ccSVD. Some of these studies
focused mostly on neuroradiological features but
there are also studies that examined clinical outcomes.
There are also primary prevention studies examining
non-clinical outcomes of SVD, mainly progress of
SVD on MRI.
Secondary prevention after lacunar stroke
Antiplatelet agents vs placebo and dual antiplatelet agents vs
aspirin or placebo. The SPS3 trial of dual vs single anti-
platelet drugs given for a mean of 3.4 years after clin-
ical lacunar stroke found that dual versus single
antiplatelet drugs increased death, and did not prevent
stroke66 or cognitive decline.67
A systematic review of antiplatelet drugs in second-
ary prevention after lacunar stroke (including SPS3)
included 17 trials (42234 participants, mean age 64.4
years, 65% male) and follow up from 4 weeks to 3.5
years.68 Compared with placebo, any single antiplatelet
agent reduced any stroke (risk ratio [RR] 0.77, 0.62–
0.97, 2 studies) and ischaemic stroke (RR 0.48, 0.30–
0.78, 2 studies), but not the composite of any stroke,
myocardial infarction, or death (RR 0.89, 0.75–1.05, 2
studies). Other antiplatelet agents (ticlodipine, cilosta-
zol, and dipyridamole) compared with aspirin, gave no
consistent reduction in stroke recurrence (RR 0.91,
0.75–1.10, 3 studies) and dual versus single antiplatelet
therapy did not confer clear benefit (any stroke RR
0.83, 0.68–1.00, 3 studies; ischaemic stroke RR 0.80,
0.62–1.02, 3 studies; composite outcome RR 0.90,
0.80–1.02, 3 studies).68
An observational study compared a PGE1 inhibitor
(alprostadil injections for 10 days followed by bera-
prost tablets up to 3 months)þ aspirin with aspirin
alone given for one year in patients with prior lacunar
ischaemic stroke and found a reduction in ischaemic
stroke (RR 0.74, 95%CI 0.65–0.88) without any
increase in haemorrhagic stroke (RR 0.92, 95%CI
0.79–1.13). However, the observational nature of the
study and limited reporting of methods and results
reduce the reliability of these data.69
Cilostazol vs other antiplatelet agents or placebo. The a sub-
group analysis of the ECLIPse trial found no effect on
WMH change after 90 days of cilostazol (a weak anti-
platelet agent) treatment in lacunar stroke patients.70



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The LACI-1 trial is a small (n¼57) trial that found
that cilostazol administered over 11 weeks to patients
with lacunar stroke was associated with less progres-
sion of WMH compared to patients not treated with
cilostazol.71
Secondary prevention after ischaemic stroke of
different types
Dual antiplatelet therapy. A substudy in the CHANCE
trial of dual vs single antiplatelet therapy given for
three weeks for secondary stroke prevention in 787
patients with minor stroke with MRI at baseline
found no interaction between WMH and antiplatelet
therapy and recurrent stroke or functional outcome at
3 months.72 Although the main CHANCE trial found
short term dual antiplatelet therapy to be beneficial in
preventing recurrent ischaemic stroke after TIA or any
subtype of minor ischaemic stroke, this substudy in
patients with MRI did not show specific benefit from
dual vs single antiplatelet agents in patients with high
versus low burden of SVD.
Cilostazol in ischaemic stroke. A systematic review of cil-
ostazol in secondary stroke prevention suggested a
reduced hazard (including less systemic bleeding) and
better stroke prevention vs placebo or other single anti-
platelet agents, including a suggestion of more benefit
in lacunar stroke.73
The PICASSO study compared cilostazol to aspirin
in ischaemic stroke patients with a previous intracere-
bral haemorrhage or multiple microbleeds. There was
no difference in white matter lesion volume change
between 254 subjects in the aspirin group and 251 in
the cilostazol group.74 However, cilostazol reduced the
incidence of any stroke in patients with mild-to-
moderate white matter changes but not in patients
with severe white matter changes, suggesting that cil-
ostazol might be effective in the earlier stages of SVD.75
Primary prevention
The ASPREE trial tested the effect of 100 mg aspirin
versus placebo on vascular events in 19114 healthy
people aged 70 years or older (or 65 years of age
among blacks and Hispanics in the United States)
over 4.7 years of follow-up, finding no effect on reduc-
ing cardiovascular disease (HR 0.95, 95%CI 0.83–
1.08), ischaemic stroke (HR 0.89, 95%CI 0.71–
1.11),76 dementia (HR 0.98, 95%CI 0.83–1.15), disabil-
ity (HR 0.85, 95%CI 0.70–1.03), or the combined end-
point of death, dementia, or physical disability (HR
1.01, 95% CI 0.92–1.11).77 However, aspirin did
increase major haemorrhage (HR 1.38, 95%CI 1.18–
1.62), intracranial haemorrhage (HR 1.5, 95% CI
1.11–2.02),76 and deaths from all causes, mainly
cancer (HR 1.14, 95% CI 1.01–1.29).78 This implies
that giving aspirin to older people, many of whom
are likely to have SVD lesions, and who do not have
a history of stroke or cardiovascular disease is unlikely
to provide benefit and may cause harm.
The Women’s Health Initiative Memory Study of
Magnetic Resonance Imaging Study is an observation-
al prospective study of long-term aspirin use after
enrolment of patients into a RCT of hormone replace-
ment therapy.79 In can be debated whether this was a
true primary prevention study because the aspirin users
more often had cardiovascular disease. After eight
years, MRI scans showed no significant difference in
WMH volume between chronic aspirin users and non-
users in unadjusted or adjusted analyses, even though
chronic aspirin users had nonsignificantly (4.8%, 95%
CI:6.8–17.9%) larger WMH volumes after covariate
adjustment.79
Several ongoing studies are noted below for a more
comprehensive overview of ongoing treatment studies
of cerebral SVD.
A study in South Korea compares aspirin vs cilos-
tazol in 254 patients with moderate or severe
cerebral white matter changes and 1 or more lacunar
infarction(s) on MRI, NCT 01932203 with a primary
outcome of change in WMH volume between baseline
and 104 weeks on MRI With secondary clinical out-
comes (ischaemic strokes, all vascular events, cogni-
tion, and disability).80
An ASPREE substudy (ENVIS-ion) described in
2012, will examine cognitive function and brain MRI
at baseline and after 3 years of treatment in 600 sub-
jects aged 70 years or older randomized to aspirin or
placebo, NCT01038583.81 Another ASPREE substudy,
the Study of Neuro-cognitive Outcomes, Radiological
and Retinal Effects of Aspirin in Sleep Apnoea
(SNORE-ASA), assesses cognition, brain MRI and ret-
inal changes in 296 subjects at study entry and after 3
years.82
The LACI-2 study is a prospective randomised open
label blinded endpoint (PROBE) trial of 400 patients
with lacunar ischaemic stroke testing the effect of cil-
ostazol (and in partial factorial design, isosorbide
mononitrate), on clinical (vascular events, cognition,
dependency, death) and imaging markers of SVD at
one year.83 The COMCID trial in Japan tests effect
of cilostazol in patients with MCI84 and the
Wardlaw et al. CXXVII
Cilostazol in Retarding Progression of Cerebral White
Matter Hyperintensities trial in China is testing the
effect of cilostazol WMH volume change with second-
ary cognitive outcomes (http://www.chictr.org.cn/com/
25/hvshowproject.aspx?id=3079).
Evidence-based Recommendation
We suggest against antiplatelet treatment in patients with
ccSVD as a means to reduce the clinical outcome events of
ischaemic or haemorrhagic strokes, cognitive decline or
dementia, dependency, death, MACE, mobility, or mood
disorders.
Quality of evidence: Very low
Strength of recommendation: Weak against interven-
tion #?
Rationale for expert consensus statement
Guidelines recommend the use of antithrombotic drugs
to reduce the risk of recurrent stroke in patients with
TIA or minor stroke, and of recurrent MI, MACE and
vascular death in patients with prior overt vascular
events.85,86 However, we found no evidence to support
the use of antiplatelet drugs such as aspirin in patients
with ccSVD who did not have any other indication,
and some evidence that giving antiplatelet drugs such
as aspirin to ccSVD would be hazardous, particularly
in older people,78 if no other indication for this treat-
ment exists.
There is a need for additional trials to better under-
stand if antiplatelet treatment may have some benefit in
ccSVD. However, such trials should only be performed
after careful considerations accounting for the results
of previous trials. Even though aspirin could be harm-
ful in this situation in older people, other weak anti-
platelet drugs which have additional pharmacological
effects could be beneficial, such as cilostazol.
Furthermore, better recognition and definition of the
atypical neuropsychiatric and cognitive symptoms that
are associated with ccSVD10 and other markers cur-
rently in investigation may help identify a group of
patients for ‘secondary prevention’, with a high
burden of disease and higher risk for future ischaemic
events and/or a lower risk of bleeding complications,
who might benefit from aspirin or equivalent drugs,
and could be tested in clinical trials.
Our literature search shows that the hitherto
reported results from RCTs, although usually emanat-
ing from small sample sizes, do not support that anti-
platelet agents have a beneficial effect on ccSVD and
adds weight to the evidence that the main underlying
pathophysiology of ccSVD may not be atherothrom-
boembolic in origin but due to other vascular dysfunc-
tion mechanisms.87
Expert Consensus Statement
Most group members agreed that:
• We advise against use of antiplatelet drugs to prevent
clinical outcomes in subjects with ccSVD when no other
indication for this treatment exists.
• With current available knowledge, the use of antiplatelet
drugs to prevent progression of cerebral SVD may be harm-
ful in older patients (from around 70 years of age) if no
other indication for this treatment exists.
PICO 3: In patients with covert small vessel diseases
[WMH and/or lacunes], does lipid lowering treatment,
compared to less intense or avoiding this intervention,
reduce ischaemic or haemorrhagic strokes (3.1), cogni-
tive decline or dementia (3.2), dependency (3.3),
death (3.4), MACE (3.5), mobility (3.6), or mood dis-
orders (3.7).
Analysis of current evidence
Three RCTs and one relevant observational study were
identified in the literature search of some relevance to
ccSVD (Figure 4, Tables 6 and 7). Due to heterogeneity
of outcomes, the data were not suitable for pooling in a
meta-analysis, so the results are summarized narrative-
ly below.
Does lipid lowering treatment (I), compared to less
intense or avoiding this intervention (C) reduce risk of
ischaemic or haemorrhagic strokes?
One study88 performed a post-hoc analysis of data
from the ROCAS (Regression of Cerebral Artery
Stenosis) study,89 which was a randomized, double-
blind, placebo-controlled trial evaluating the effects
of statins upon asymptomatic middle cerebral artery
(MCA) stenosis progression among stroke-free individ-
uals. The primary focus of this post-hoc analysis of 207
subjects was to assess WMH progression as an out-
come (see below), but the study also reported stroke
as an outcome with no difference between groups (3
events in each arm).
Guo et al90 reported a combination of a prospec-
tive population-based cohort study (N¼827) and a
subset of patients from a randomized, double-blind,
CXXVIII European Stroke Journal 6(2)
placebo-controlled clinical trial21,91 which had a 2x2
factorial design investigating BP lowering and lipid
lowering with rosuvastatin 10mg mixed regimen in
elderly Chinese individuals (N¼227). The primary
outcome for this study was WMH progression (see
below), but incident stroke was a secondary outcome.
The risk of incident stroke was significantly lower in
the rosuvastatin group than the placebo group (HR:
0.56, 95% CI: 0.37 to 0.84, P<0.001), a finding repli-
cated in the observational cohort (HR: 0.60, 95% CI:
0.37 to 0.98).
Does lipid lowering treatment (I), compared to
avoiding this intervention (C) reduce risk of cognitive
decline or dementia?
We identified two RCTs. The first was a randomized
placebo controlled factorial 2x2 design of BP lowering
(telmisartan) and lipid lowering (rosuvastatin) in 732
elderly hypertensive Chinese patients who were already
taking hydrochlorothiazide.21 The MMSE and DRS
were secondary outcomes and they both declined
more slowly in patients taking rosuvastatin. Of note,
the patients in this report are from the same RCT as
reported by Ji, 201891 and Guo et al. 90
Zhang et al.92 reported a RCT of rosuvatatin plus
nimodipine versus a control arm of nimodipine alone
administered for six months in 120 patients with mild
ccSVD. The third outcome listed was MoCA at six
months. Data given in Figure 3 (not in text) of the
publication suggests the average MOCA score was 18
in the active and 17 in the control group prior to the
trial treatment, and were 22 in the treatment group and
19 in the control group after six months’ treatment
(P<0.05).
Does lipid lowering treatment (I), compared to
avoiding this intervention (C) reduce risk of
dependency?
Zhang et al92 also report on Activities of Daily Living.
Data from Figure 4 (not given in text) shows ADL
scores were higher in both groups at the end of six
months treatment than pre-treatment and were highest
in the active treatment group (ADL score of 69 in
active vs. 61 in control groups, P<0.05)
Figure 4. Search results PICO 3.
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Does lipid lowering treatment (I), compared to
avoiding this intervention (C) reduce death?
We found no RCT or observational studies related to
this question.
Does lipid lowering treatment (I), compared to
avoiding this intervention (C) reduce MACE?
One aforementioned study88 performed a post-hoc sub-
group analysis of a secondary outcome in patients with
asymptomatic MCA stenosis and found no difference
in the rate of myocardial infarction between the inter-
vention (simvastatin) and the control arm.
Does lipid lowering treatment (I), compared to
avoiding this intervention (C) reduce risk of mobility
impairment?
We found no RCT or observational studies related to
this question.
Does lipid lowering treatment (I), compared to
avoiding this intervention (C) reduce risk of mood
disorders?
We found no RCT or observational studies related to
this question.
Additional information
We identified six studies (of which three publications
report on patients from the same trial21,90,91) that
assessed the effect of lipid lowering on SVD lesions
progression on neuroimaging, in addition to the two
publications mentioned above. We believe it relevant
to report the results of these trials, although the clinical
implications of reducing the burden of ccSVD on neu-
roimaging are not yet established (Table 8).
A brain MRI and cognitive function substudy of a
RCT enrolled 732/1244 Chinese hypertensive patients
aged >60 years randomized to rosuvastatin 10mg/day
or placebo91 from which clinical outcomes were provid-
ed in Zhang et al.21 Of 688 patients with pre- and post-
treatment period MRI and included in the analysis,
WMH volume and the Fazekas rating scale were deter-
mined at baseline and after a median follow-up of 61.8
months on brain MRI. The outcomes included changes
in WMH volume, new-incident Fazekas scale score >2,
new-incident lacunes, and new-incident microbleeds.
The RCT found a lower increase in WMH volume in
the rosuvastatin vs control groups, respectively 1.20þ/-
0.46 vs 1.72þ/-0.43 mL, adjusted P< 0.001. Compared
with the rosuvastatin group, the risk of new-incident
Fazekas scale score >2 was higher (HR 2.15, 95% CI
1.44, 3.20; P< 0.001), and of new-incident lacunes was
higher (HR 1.86, 95% CI 1.12, 3.08; P ¼0.016) in the
placebo group. There was no significant effect of rosu-
vastatin on the risk of new-incident microbleeds.
A substudy of the PROSPER trial in 535 partici-
pants tested the effect of pravastatin vs placebo on
WMH progression over 33 months, finding no effect
(MD 1.1 vs 1.1 cm3, P¼0.73).93
Mok et al, in the ROCAS RCT trial substudy,88
found no effect of simvastatin 20mg daily versus pla-
cebo for two years on WMH progression in 208
patients with asymptomatic MCA stenosis and a
median age 63 years, but most patients (about 70%)
had very few or no WMH at baseline. In the few
patients with a high WMH burden (2-3 cm3 at base-
line), there was some evidence of reduced WMH pro-
gression in the patients allocated to simvastatin (n¼12,
23.2% WMH increase) versus control (n¼15, WMH
increase 58.2%), adjusted P¼0.019.
Guo et al90 examinedWMHprogression in a subset of
patients from the same clinical trial of statins vs control
reported above.21,91 They included 227 subjects from the
clinical trial and 781 subjects from a cohort study split
according to statin (about one fifth) use or not (about 4/
5ths) users, with average follow-up of 63 months. In the
227 participants in the RCT, half allocated to rosuvasta-
tin 10mg daily and half to placebo, the risks of progres-
sion ofWMH (HR: 0.41, 95%CI: 0.23 to 0.72, P<0.001)
and lacunes (HR: 0.42, 95% CI: 0.26 to 0.68, P<0.001)
were significantly lower in the rosuvastatin group than
the placebo group after adjustment for confounders BP
and incident stroke. A similar pattern of reduction in
WMH and lacune progression was seen in the observa-
tional study amongst statin users vs non-users.
The Mayo Clinic Study of Aging (MCSA)94 is a
prospective observational population-based study
which included 1160 residents in Olmsted County,
Minnesota (USA) aged >65 years. The study included
neuropsychological assessment, cerebral PET, blood
and cerebrospinal fluid biomarkers. Subjects were clas-
sified as statin-treated, statin-untreated (3 months of
treatment), and long-term statin-treated (5 years of
treatment). The study assessed WMH on structural
brain MRI and found that statin use did not influence
neuroimaging markers, with no difference between
lipophilic and hydrophilic statins. The study provided
no information on clinical outcomes.
A prospective case-control study performed in a
memory clinic included 474 patients classified as with
“no cognitive impairment”, “cognitive impairment no
dementia”, and “dementia”.95 Patients underwent MRI
scans assessing lacunes, microbleeds, and WMH after a
2-year follow-up. The study found that use of statins
was associated with a decreased risk of incident lacunes
(OR: 0.15, 95% CI: 0.04, 0.61) but not with WMH
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progression (OR: 1.09, 95%CI 0.53–2.28) or with new
microbleeds (OR: 1.81, 0.73–1.99). This study provided
no clinical outcomes.
We conducted a random effects meta-analysis of
WMHprogression in the three trials comparing ’absolute
progression ofWMH volume’ for each group (control vs
intervention). We used WMH volume mean and SD,
converting medians to means where needed (Figure
5).96 The standardised mean difference was –0.40, 95%
CI -1.24, 0.46, p¼0.37, with substantial between trial het-
erogeneity (I-2¼ 98.294, Q¼117.204). The sparse infor-
mation from the trials and skewed distribution of WMH
volumes reduces the reliability of this analysis.
Overall, the six papers (four studies) suggest a possi-
ble role of statins, in particular rosuvastatin, in prevent-
ing the progression of neuroimaging signs of ccSVD, but
provide no clinical outcomes and three of the four stud-
ies are further limited by their observational design.
The ACCORD MIND trial46 randomised 1538 par-
ticipants with type 2 diabetes (who could be considered
a high risk group for ccSVD) to lipid lowering with a
fibrate versus placebo. There was no difference in Digit
Symbol Substitution Test mean scores between fibrate
versus placebo lipid groups (lipid difference between
means, 0.08 [0.92 to 0.76]; P¼0.85) or for the
three other cognitive tests, at 40 months. Among 503
participants with baseline and follow-up MRI, there
was no difference in total brain volume at 40 months
between fibrate (change from baseline -12.9, -16.1 to
-9.8) and control (change from baseline -14.1, 95%CI
-17.1, -11.1) adjusted P¼0.59.
A systematic review and meta-analysis of four trials
testing the effect of intensive versus guideline lipid low-
ering on post-stroke cognitive impairment, comprising
623 participants with stroke including lacunar stroke
found those allocated to intensive statin versus control
had better cognitive outcomes (mean difference on
ACE-R score, 1.34, 95%CI 0.15–2.53, p¼0.03).97
Evidence-based Recommendation
We did not find enough evidence of high enough quality on
prevention of clinical outcomes in ccSVD to make a
definitive recommendation on lipid lowering. However, we
recognise that lipid lowering is effective in primary preven-
tion in those at high risk of vascular events.
Quality of evidence – Very low 
Strength of recommendation - Weak for intervention "?
Rationale for expert consensus statement
Primary prevention of cardiovascular disease is recom-
mended in subjects at the highest cardiovascular risk,
including at older ages, to prevent vascular events.98,99
Lipid lowering by several agents in older subjects
reduced stroke, MI, and cardiovascular death with sim-
ilar effect to those aged <75yrs; however, limited data
suggested no effect on cognitive outcomes.100 Although
the role of elevated plasma lipid levels might be less
relevant in ccSVD in comparison with, for example,
atherothrombotic strokes, it is important to assess
whether lipid lowering treatments can decrease the
risk of cardiovascular outcomes in patients with ccSVD.
Expert consensus statement
The group members were narrowly in favor that:
• Lipid lowering with statins could be considered in patients
with ccSVD, even when no other indication for statin treat-
ment exists, with the aim of delaying the progression of
ccSVD, although the clinical implications of this delayed pro-
gression remain to be proven.
PICO 4: In patients with covert cerebral small vessel
diseases [WMH and/or lacunes], do lifestyle interven-
tions [smoking cessation, weight reduction, dietary
interventions, physical exercise, cognitive/social inter-
ventions, sleep/CPAP, or a mixture of these], compared
to less intense or avoiding these interventions, reduce
ischaemic or haemorrhagic strokes (4.1), cognitive
decline or dementia (4.2), dependency (4.3), death
(4.4), MACE (4.5), mobility (4.6), or mood disorders
(4.7).
Figure 5. Meta-analysis Lipid lowering and WMH progression. Blue: Covert Small Vessel Disease study population; Green:
Hypertensive and/or high vascular risk study population.
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Analysis of current evidence
Lifestyle interventions aim to control obesity, hyper-
tension, mental health, diabetes, dyslipidaemia and
sleep obstructive disorders by avoiding harmful
habits, increasing aerobic physical activities, adopting
dietary measures, or improving cognitive skills.
Addressing lifestyle factors are strongly recommended
(Level I recommendation) in the primary prevention of
stroke and cardiovascular diseases.101,102 The World
Health Organization Guidelines recommend physical
activity and smoking cessation for the primary preven-
tion of cognitive decline and dementia, but the level of
evidence is moderate for the efficacy of dietary inter-
vention and low for cognitive and social interven-
tions.103 Therefore, we have assessed whether
evidence exists about lifestyle interventions in the pop-
ulation with ccSVD, who might benefit more from life-
style interventions given the tight association between
SVD and vascular risk factors, but also might be prone
to higher risk of adverse events e.g. from falls due to
physical activity compared to healthy subjects. It
should be noted that all RCTs identified were graded
as having a serious or very serious risk of bias and low
certainty surrounding the estimate of efficacy
(Figure 6, Tables 9 and 10). We included in our litera-
ture assessment RCTs and prospective observational
studies since cross-sectional studies would not allow
assessing the effect of interventions, but only
associations.
Physical exercise
Two RCTs and three relevant observational studies of
physical exercise were identified in the literature search.
Due to varying outcomes, the data were not suitable
for pooling in meta-analysis, so the results are summa-
rized narratively below.
Physical exercise and ischaemic or haemorrhagic strokes. The
literature search did not find any RCTs investigating
the impact of physical exercise on the incidence of
ischaemic or haemorrhagic strokes in individuals with
ccSVD.
Figure 6. Summary of search results PICO 4.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































An observational analysis from the Radboud
University Nijmegen Diffusion tensor and Magnetic
resonance imaging Cohort (RUNDMC) study with a
total of 503 participants with SVD on neuroimaging
without dementia (some participants may have had
TIA or minor stroke) suggested that higher baseline
physical activity as assessed with a questionnaire is
related to lower incidence of cerebrovascular events
(composite endpoint consisting of TIAs, ischaemic
and haemorrhagic strokes and vascular dementia)
(adjusted HR: 0.58, 95%CI: 0.36–0.96) over 9-year
follow-up. However, there was no association between
physical activity and lacunar stroke or WMH
progression.104
Physical exercise and cognitive decline or dementia. Two
RCTs provided results of the influence of physical
interventions on cognitive decline.
A single-blinded RCT (Promotion of the Mind
Through Exercise, PROMOTE) compared a 6-month,
thrice-weekly, progressive aerobic exercise training
with usual care and education in 71 individuals with
SVD (35 per group). At the end of the treatment
period, the intervention group had significantly
improved global cognitive performance (ADAS-Cog)
compared to the control group (-1.71 point difference,
95%CI: -3.15–-0.26), but the difference was not signif-
icant after additional 6-month follow-up. The interven-
tion had no significant effect on executive functions
(EXIT-25).105 A subgroup analysis from the same
RCT (10 and 11 per group) showed that subjects rand-
omised to aerobic training significantly improved in
flanker task performance, compared to controls, sug-
gesting improved selective attention and response
inhibition.106
Another RCT compared the efficacy of a 24-week
aerobic dance training relative to stretching and health
education in 110 older adults (54 and 56 per group)
with SVD on multiple cognitive tests administered at
12, 24 and 36 weeks. Significant effects of exercise were
reported on executive function (trails test) at 24 weeks,
and on delayed recognition (list learning test) at 24 and
36 weeks. Group differences were non-significant in
other tests measuring global cognition, memory or
processing speed.107
An observational 3-year follow-up study, the
Leukoaraiosis and Disability Study (LADIS), included
639 individuals with age-related WMH and no disabil-
ity at enrolment. Self-reported physical activity at base-
line was associated with reduced risk of cognitive
decline and incident dementia (HR 0.64; 95% CI,
0.48–0.85), and vascular dementia in particular (HR
0.42; 95% CI, 0.22–0.80), independently of confound-
ers including WMH severity and previous and incident






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































analysed in a subgroup of 282 subjects who had not
progressed to MCI or dementia. Physical activity was
associated with higher baseline scores of processing
speed and executive functions, and with less decline
in executive functions at follow-up.109
Physical exercise and dependency. Dependency in activities
of daily living was addressed in two RCTs,105,107 nei-
ther of which found a significant effect of physical exer-
cise on functional abilities.
Physical exercise and death. No RCTs addressing the
effect of physical exercise on mortality were identified.
The observational RUNDMC study has reported that
in 503 participants with SVD, higher baseline physical
activity level as evaluated with a questionnaire was
related to a lower all-cause mortality (adjusted HR:
0.69, 95%CI: 0.49–0.98) over 9-year follow-up.104
Physical exercise and MACE. The literature search did not
identify any RCTs or observational studies addressing
this question.
Physical exercise and mobility. The RCT comparing the
effect of 24-week aerobic dance training with stretching
and education (54 and 56 per group) reported a signif-
icant treatment effect on mobility as evaluated with the
timed-up-and-go test at 12 weeks, but not in walking
capacity or balance, and none of the group differences
were longer significant at 24 and 36 weeks.107
Physical exercise and mood disorders. The aforementioned
RCT comparing the effect of 24-week aerobic dance
training with stretching and education (54 and 56 per
group) found no treatment effect on mood as evaluated
with the 15-item Geriatric Depression Scale.107
Other lifestyle interventions (non-physical activity)
Non physical activity lifestyle interventions and risk of
haemorrhagic or ischaemic stroke. The literature search
did not identify any RCTs or high quality observation-
al studies addressing this question.
Non physical activity lifestyle interventions and risk of cognitive
decline or dementia. Cognitive training – A RCT (the
Cog-vaccine trial110) randomized 60 patients with sub-
cortical vascular impairment but no dementia to com-
pare the intervention of a 7 week program of
multidomain adaptive computerized cognitive training
with an active control of a programme of fixed atten-
tion and processing speed tasks. At the end of the 7
week period, those in the intervention arm showed a
significant improvement in the MoCA test, but this
difference was not maintained at 6 month follow up.
Dietary supplements – Bowman et al111 performed a
randomised double blind placebo controlled trial (total
n¼102) of fish oil (marine n-3 polyunsaturated fatty
acids) compared with a placebo of soybean oil in
older patients with evidence of WMH accumulation.
Executive cognitive function, measured as an explor-
atory secondary outcome did not differ between the
groups after three years.111
Sleep interventions – we found one study112 that per-
formed a randomised double blind placebo controlled
trial of trazodone for four weeks in patients with vas-
cular risk factors and evidence of SVD on brain scan-
ning who had insomnia. Forty patients were recruited,
30 completed the trial (mean age 65 years) and the
authors reported no significant change in total
MoCA (the primary outcome at four weeks) but did
report small significant improvements in the concentra-
tion and recall items of the MoCA for the intervention
group (see Table 9).
Non physical activity lifestyle interventions and risk of
dependency. The literature search did not identify any
RCTs or high quality observational studies addressing
this question.
Non physical activity lifestyle interventions and risk of death.
The literature search did not identify any RCTs or high
quality observational studies addressing this question.
Non physical activity lifestyle interventions and risk of MACE.
The literature search did not identify any RCTs or high
quality observational studies addressing this question.
Non physical activity lifestyle interventions and risk of mobility.
The literature search did not identify any RCTs or high
quality observational studies addressing this question.
Non physical activity lifestyle interventions and risk of mood
disorder. The literature search did not identify any
RCTs or high quality observational studies addressing
this question.
Additional information
Direct evidence of the impact of life-style interventions
on clinical outcomes in ccSVD is sparse. RCTs with
participants with memory complaints or MCI and no
definition of SVD at enrolment (NeuroExercice, AIBL
Active) have found no intervention effects of aerobic
exercise on cognitive or imaging outcomes.113,114
However, an RCT with elderly individuals at-risk for
dementia from the general population (FINGER) has
shown that a multidomain intervention including diet,
exercise, cognitive training and vascular risk monitor-
ing has beneficial effects in improving and maintaining
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cognitive functioning.115 A pooled analysis of 322 indi-
viduals from two RCTs targeting lifestyle and vascular
risk factors with multi-domain interventions to prevent
post-stroke cognitive impairment found limited evi-
dence of benefit on attention but not on other cognitive
domains.116 An RCT (AFIVASC) is ongoing to assess
the efficacy of a 6-month physical activity program on
neuropsychological and neuroimaging outcomes in
patients with vascular cognitive impairment.117
Among community-dwelling older individuals, the
observational population-based Northern Manhattan
Study has suggested that moderate or heavy physical
activity at baseline is associated with lower prevalence
of subclinical brain infarcts but not WMH on MRI
scan 6 years later.118 Another prospective observation-
al study, The Shiga Epidemiological Study of
Subclinical Atherosclerosis, in healthy Japanese men
has reported a relationship between higher average
step count at baseline and lower burden of WMH
and lacunar infarcts, but not microbleeds on MRI
scans approximately 6 years later.119
Existing guidelines101 promote lifestyle factors such
as physical activity (moderate to vigorous intensity aer-
obic physical activity at least 40 min/day 3 to 4 days/
week is recommended), diet rich in fruit and vegetables,
Mediterranean diet supplemented with nuts, over-
weight reduction and quitting smoking (assisted by
counselling in combination with drug therapy) to
reduce the risk of stroke in adults with no history of
stroke or TIA.101 The beneficial effects of physical
exercise are clear in the general population and current
evidence does not suggest any harm of such activity in
ccSVD.
The role of dietary intervention in the prevention of
stroke was summarised in a recent review.120 The
review found that B-group vitamins (folic acid, B6,
B12), niacin, or vitamin D supplementations had no
benefit on recurrent stroke; folic acid alone or with
low dose vitamin B12, but not with high doses of
B12, can reduce stroke risk in geographical areas
where dietary folate is low. Omega-3 fatty acids overall
had no effect on stroke incidence or for ischaemic
stroke and increased the risk for haemorrhagic
stroke. Mediterranean diet decreased the risk of
stroke and the DASH diet effectively reduced BP.
The review concluded that patients at risk of stroke
should be advised to follow a Mediterranean-style
diet and to increase fruit and vegetable consumption.
Homocysteine lowering with vitamins B6, B9, or B12
reduced the risk of stroke, but not myocardial infarc-
tion, death, or serious adverse events compared with
placebo.121 Another review found no effect of vitamin
C for primary prevention of cardiovascular disease.122
A further review found no effect of omega-6 fats for the
primary and secondary prevention of cardiovascular
disease except for MI.123
A cross-sectional study124 suggested that smoking
cessation is associated with improved white matter
structural integrity and better cognition compared
with not stopping smoking.
Evidence-based Recommendation
In patients with ccSVD, we suggest that physical exercise has
beneficial effects on cognition and possibly also on mobility,
incidence of cerebrovascular events and all-cause mortality,
and therefore, recommend regular physical activity in gen-
eral. However, we cannot make recommendations on a spe-
cific physical intervention based on current evidence.
Quality of evidence: Very Low 
Strength of recommendation: Weak for intervention "?
In patients with ccSVD there is no clear evidence that other
non-physical lifestyle interventions have beneficial effects on
clinical outcomes.
Quality of evidence: Very low 
Strength of recommendation: No recommendation
Expert consensus statement
All group members suggest that:
• There is no direct evidence to suggest that any specific
lifestyle interventions prevent clinical outcomes in patients
with ccSVD.
• However it is reasonable to promote healthy lifestyle inter-
ventions as recommended in primary prevention for vascu-
lar disease (including but not limited to maintaining healthy
body weight, promoting exercise, avoiding smoking and
excess alcohol, eating a healthy, balanced diet) in patients
with ccSVD.
PICO 5: In patients with covert cerebral small vessel
diseases [WMH and/or lacunes] who may (or may not)
require glucose lowering therapies, do drugs which
reduce plasma glucose levels, compared to less intense
or avoiding these interventions, reduce ischaemic or
haemorrhagic strokes (5.1), cognitive decline or demen-
tia (5.2), dependency (5.3), death (5.4), MACE (5.5),
mobility (5.6), or mood disorders (5.7)?
Analysis of current evidence
The literature search did not identify any RCT or
observational study directly addressing these PICO
questions. No study investigated specifically glucose
lowering therapies in patients with ccSVD (Figure 7).
We therefore examined whether there was any evidence
to guide ccSVD management in people living with
Wardlaw et al. CXLIII
diabetes, although relevant studies addressing this topic
also proved to be scarce.
In a Cochrane review of 32 studies, four RCTs com-
paring metformin alone to the combination of metfor-
min with second or third generation sulphonylurea
showed that non-fatal stroke occurred in 14/2098
(0.7%) participants under metformin versus 8/2995
(0.3%) under combined treatments (RR 2.21, 95% CI
0.74 to 6.58; P¼ 0.15).125 No benefit was detected,
either, for global mortality, cardiovascular mortality
or fatal stroke and there were no data on dementia.125
In the ACCORD-MIND substudy cohort of 502
people with diabetes followed over 40 months, WMH
progression did not differ between intensive treatment
with target HbA1C <6% and standard treatment with
target HbA1C between 7 and 8% (0.92 1.31 vs
0.93 1.06 cm3, p¼ 0.917).55 An earlier analysis
found more WMH in the intensive glycaemic control
group at 40 months (difference 0.18cm3 - 95% CI 0.16–
0.2, p¼0.015), particularly in patients aged less than 60
years.126 However, there was less loss of total brain
volume at 40 months in the intensive treatment than
in the control group (difference in volume 4.6, 95% CI
2.0 to 7.3, cm3 respectively, p¼0.0007).126 The protec-
tive effect of intensive glycaemic control on preserving
brain volume was confirmed in later analyses, where
however an interaction between BP lowering and
glycaemic control on total brain volume was
detected.46 However, there was no difference between
intensive and guideline glycaemic control groups in any
of four cognitive tests (e.g. Digit Symbol Substitution
Test score difference in mean scores at 40 months 0.32,
95% CI –0.28 to 0.91; p¼0.2997) in the 2957/2977
MIND participants with cognitive data, and the overall
MIND trial had stopped early due to excess mortality
in the intensive glycaemic control arm.126
Additional information
Diabetes has been repeatedly but inconstantly associ-
ated with the extent of WMH or with their progression
in several population-based studies.127 Moreover,
markers of diabetic retinal or kidney microangiopathy
as well as diabetic neuropathy have been also associat-
ed with a larger extent of WMH.127 In the Maastricht
study, a population-based cohort of 2228 participants,
both HbA1c, fasting and 2-h post-load plasma glucose
levels were related to the volume of WMH and pres-
ence of lacunes in individuals with pre- or type 2 dia-
betes.128 Similarly, type 2 diabetes was associated with
more lacunes, WMH and brain volume loss in 851
patients presenting to a memory clinic with vascular
cognitive impairment.129 Among 1713 participants of
the Atherosclerosis Risk in Communities -
Figure 7. Summary of search results PICO 5.
CXLIV European Stroke Journal 6(2)
Neurocognitive Study (ARIC-NCS), only patients with
diabetes with HbA1c 7.0% but not diabetic or non-
diabetic individuals with HbA1c <7.0% had an
increased burden of WMH.130 Among 618 non-
demented elderly Medicare recipients from Northern
Manhattan, HbA1c as a continuous or categorical var-
iable was also found to be associated with a higher
number of brain infarcts, WMH volume and decreased
total white matter, grey matter and hippocampus vol-
umes cross-sectionally and with a significant decline in
only grey matter volume longitudinally.131 Conversely,
other studies suggest that the diabetic status,132 dura-
tion of diabetes,130,133 glucose variability,134 or ethnic
origin,135 but not the HbA1c level,134 are crucial in the
development of cerebral microvascular lesions.
A pooled analysis of 3950 subjects living with diabe-
tes from five population-based cohorts found that insu-
lin use vs no insulin use was associated with increased
risk of incident dementia and greater decline in cognitive
function, which remained significant after adjustment
for renal function and excluding persons whose diabetes
was managed with lifestyle changes only, but not after
using brain MRI measures.136 In the same analysis,
there was no association between sulphonylurea use
and incident dementia, but metformin use was associat-
ed with increased incident dementia in covariate-
adjusted analyses.136 There were no associations of the
three drugs with brain or WMH volumes.136 Multiple
potential biases in these observational studies may
explain the discrepant results (type of population, eth-
nicity, social context, education, age, duration of diabe-
tes, type and duration of antidiabetic treatment, imaging
measures, associated vascular risk factors).
Finally, there is some evidence from observational
studies that diabetes or high levels of plasma glucose
over extended periods are deleterious to the brain and
may promote the development of SVD.127 There is also
some evidence that long-term hyperglycaemia may pro-
mote cognitive decline in persons living with diabetes
patients. Such effects may occur with the extension of
cerebral SVD lesions, but also, independently, in con-
nection with grey or white matter atrophy.131
Evidence-based Recommendations
In patients with diabetes who may also have ccSVD, we
recommend the use of current guideline-based glucose low-
ering therapies, including recommended glucose and
HbA1C targets, as appropriate to the management of the
individual patient’s diabetes. There is no justification for rec-
ommending any particular glucose-lowering therapy for this
purpose.
We suggest against glucose lowering in patients with ccSVD
who do not have any indication for glucose control.
Quality of evidence: Very low 
Strength of recommendation: No recommendation
Rational for expert consensus statement
The quality of available studies does not allow the
guidelines writing group to provide any evidence-
based recommendations for a specific glucose lowering
therapy or for targeting a specific plasma glucose level
or HbA1c in ccSVD patients with or without diabetes.
There is also no evidence that a strict control of gly-
caemia may benefit patients with ccSVD who also have
diabetes. There is no evidence to suggest that diabetes
care guidelines137 should be altered in patients who also
have ccSVD. Additional studies are warranted in per-
sons living with diabetes with SVD to determine the
ideal plasma glucose level below which extension of
SVD lesions and clinical manifestations are prevented,
whether specific glucose lowering treatments are more
effective, and whether particular individual risk factors
should be taken into consideration. Further prospec-
tive and randomised data are needed for this purpose.
Expert Consensus Statement
All group members agree that in prediabetes or diabetic
patients with ccSVD:
• Glycaemic level should be appropriately monitored so as
to be controlled according to the standards of medical care.
• We cannot advise any specific agent for obtaining appro-
priate glycaemic control.
• There is currently insufficient evidence to recommend
targeting a specific glucose or HbA1c level distinct from
the standard targets.
• There is no evidence to support any therapeutic interven-
tion to reduce the normal glucose level.
PICO 6: In patients with covert cerebral small vessel
diseases [WMH and/or lacunes], do conventional anti-
dementia drugs [e.g. memantine, donepezil, galant-
amine, rivastigmine, etc.], compared to avoiding these
interventions, reduce cognitive decline or dementia.
ccSVDcarries an increased risk for development of cog-
nitive complaints and cognitive impairment. Vascular cog-
nitive impairment (VCI) captures all cognitive disorders
related to cerebrovascular injury, from cortical ischaemic
or haemorrhagic stroke to SVD.43 VCI ranges clinically
frommild cognitive impairment, defined as impairment in
at least one cognitive domain without clear influence on
daily activities (Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition, DSM-V, ‘minor neuro-
cognitive disorder’), to fully developed dementia, defined
as cognitive impairment in at least 2 cognitive domains
which affects the person’s independent functioning
(DSM-V ‘major neurocognitive disorder’). Dementia
may be ‘pure’ vascular or mixed with degenerative
Alzheimer’s disease. Contrary to the common statement
Wardlaw et al. CXLV
that VCI due to SVD typically affects the cognitive
domains of processing speed and executive functions, it
affects any cognitive domain, including memory.11,12
Deficits in cholinergic and glutamatergic pathways
are involved in cognitive decline in Alzheimer’s dis-
ease.138,139 There is also evidence for cholinergic
involvement in VCI.140 Cholinesterase inhibitors
increase acetylcholine levels by decreasing the rate at
which it is broken down, thereby boosting cholinergic
neurotransmission. Memantine is an NMDA receptor
antagonist and protects against excessive glutamate-
induced excitotoxicity which is hypothesized to be
involved in the pathogenesis of Alzheimer’s disease,
and also in vascular brain injury.
Based on these mechanisms of action in dementia, the
working group defined a PICOquestion onwhether these
conventional anti-dementia drugs could reduce cognitive
decline in patients with ccSVD. We searched for i) the
cholinesterase inhibitors donepezil, galantamine and
rivastigmine, ii) memantine, and iii) other anti-dementia
drugs not covered in the other PICO questions.
Analysis of current evidence
Cholinesterase inhibitors
We found no studies on donepezil, galantamine or riva-
stigmine meeting our criteria in ccSVD (Figure 8,
Tables 11 and 12).
Memantine
We found no studies on memantine in ccSVD.
Other anti-dementia drugs
We found one RCT testing nicergoline, an ergot deriv-
ative with several mechanisms of action, i.e. it induces
vasodilation and increases arterial blood flow, and
enhances cholinergic and catecholaminergic neuro-
transmitter function. The study, performed 1990-
1995, included 61 hypertensive patients with leukoar-
aiosis on brain CT and no clinical signs of cognitive or
neurological disorders.141 Patients were randomly and
double-blind assigned to nicergoline 60mg/day or
Figure 8. Summary of search results PICO 6.







































































































































































































































































































































































































































































































































































































































































































































































placebo over a period of two years. Patients on nicer-
goline showed attenuated deterioration at the last visit
(protocolled at two years, but unclear dropout) on
three out of four memory tests, and two out of 10
attention and concentration tests. The effects on psy-
chomotor and verbal function, and global cognitive
performance, were non-significant. The quality of evi-
dence, based on this single study with small sample size
and multiple cognitive tests and uncertainty about
dropout and a clinically relevant effect, was graded as
very low because of serious risk of bias and very serious
imprecision.
Additional information
We believe there is both an under representation and
under recognition of cognitive complaints and cogni-
tive deficits in patients with SVD. Per definition, SVD
is not ‘covert’ anymore when cognitive impairment,
even mild, has been shown with formal cognitive test-
ing. However, both (elderly) patients and their care-
givers often do not notice or feel affected by mild and
gradual cognitive decline, and also professionals often
do not further explore cognition, even when vascular
brain injury has been shown on imaging. We encourage
more attention to cognitive impairment by actively
asking for complaints, and performing cognitive
screening by using appropriate tools.
Cholinesterase inhibitors and memantine
Cholinesterase inhibitors and memantine are mainly
indicated for treatment in Alzheimer’s disease. In
VCI, several RCTs on these anti-dementia drugs have
been performed. Most of these focused on vascular
dementia and only few studies included mild VCI.
A recent comprehensive Cochrane review assessed
the efficacy and safety of cholinesterase inhibitors in
vascular dementia and other VCIs.142 The review
included eight trials (4373 patients), three on donepezil,
three on rivastigmine and two on galantamine. All
trials included patients with vascular dementia, and
one study also included post-stroke-cognitive impair-
ment-no dementia. Donepezil and galantamine had
small, unlikely to be clinically relevant effects, and riva-
stigmine had no important effect on cognition.
We mention for completeness one trial that tested 18
weeks of donepezil versus placebo in patients with mild
cognitive impairment due to CADASIL.143 In 161
patients, there was no benefit of donepezil on the pri-
mary outcome (vascular AD assessment scale cognitive
subscale) and small improvements in performance on
Trails tests.
Another Cochrane review on memantine for demen-
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VCI was not included. This review suggested that there
is probably a small clinical benefit on cognitive func-
tion in vascular dementia for memantine compared
with placebo. A post-hoc analysis indicated greater
benefits in patients with more severe vascular dementia.
The Chinese clinical practice guideline for cognitive
impairment of cerebral SVD, published in 2019, con-
cluded there is level IIa evidence for the use of done-
pezil, galantamine and memantine in vascular
dementia, but no recommendations were made for
ccSVD or mild VCI.145
Other anti-dementia drugs
Dl-3-n-butylphthalidle (NBP), an anti-VCI drug with
multiple effects developed in China, was studied in a
single, randomized, double-blind, placebo-controlled
trial in 281 patients with VCI without dementia.146
Over a 6-month treatment period, NBP was effective
for improving cognitive and global functioning. This
substance has not been studied in ccSVD.
Several substances that are available as dietary sup-
plements, such as Ginkgo Biloba147 and CDP-choline
or citicoline,148,149 have been studied in VCI and vas-
cular dementia. Few studies were done in mild VCI,
and none in ccSVD.
A Cochrane review (2009, not updated thereafter)150
on Ginkgo Biloba for cognitive impairment and
dementia concluded that the evidence that Ginkgo
Biloba has predictable and clinically significant benefit
for people with dementia or cognitive impairment is
inconsistent and unreliable. No subgroup analysis for
(mild) VCI or vascular dementia could be done. A
meta-analysis in 2015 concluded that Ginkgo Biloba
is able to stabilize or slow decline in cognition in sub-
jects with cognitive impairment and dementia, however
there was no specific information on ccSVD, (mild)
VCI or vascular dementia.151 In 2017, a small random-
ized, double-blind, placebo-controlled 6-month trial on
Ginkgo Biloba in patients with VCI was published.
However, VCI was unclearly defined as ‘cerebrovascu-
lar insufficiency’, and although there was a positive
effect on the Clinical Global Impression scale, this
was a per protocol analysis of only 58/90 patients
who finished the study and it was concluded that fur-
ther studies on efficacy and safety are still needed.147
The IDEALE study assessed the effect of a 9-month
treatment with citicoline (500mg b.d.) in 349 patients
with mild VCI, in a non-randomized open label setting.
In the active treatment group, MMSE scores remained
stable (22.4 at baseline and 22.9 at 9 months) while in
the control group MMSE score declined 2 points (21.5
to 19.6 at 9 months).149
Other drugs, such as Cerebrolysin,152 huperzine153
and actovegin154 have been studied in vascular
dementia or poststroke cognitive impairment, but not
specifically in mild VCI nor in ccSVD.
We are not aware of any ongoing trials with (con-
ventional) anti-dementia drugs such as are used in
Alzheimer’s disease in ccSVD; few trials are ongoing
in mild VCI aiming at reducing cognitive decline, such
as a Chinese trial with i.m.-injections of mouse
nerve growth factor in patients with VCI (https://clini
caltrials.gov/ct2/show/NCT04041349), and the
CONIVaD trial,155 a RCT of nimodipine plus choline
alphoscerate (a cholinergic precursor) or placebo
during 12 months in patients with mild VCI due to
SVD.
Evidence-based Recommendation
In patients with ccSVD, we suggest against the use of con-
ventional anti-dementia drugs, including cholinesterase
inhibitors or memantine, as a means to reduce cognitive
decline or dementia.
Quality of evidence: Very low 
Strength of recommendation: Weak against interven-
tion #?
Rational for expert consensus statement
These studies on conventional and other anti-dementia
drugs in VCI and vascular dementia do not give much
reason to presume any major effect on reduction of
cognitive decline in mild VCI due to SVD or truly
ccSVD, although it must be said that cognitive impair-
ment in SVD develops slowly and the benefit may only
show over many years, while the aforementioned trials
only lasted 24 to 28 weeks. Moreover, the conventional
anti-dementia drugs like cholinesterase inhibitors are
symptomatic and do not act on the pathophysiological
mechanism in SVD, so it is unlikely that they will be of
any preventive benefit in truly covert cSVD. Trials in
mild VCI and ccSVD are needed, with adequate dura-
tion of follow-up and appropriate neuropsychological
testing covering the cognitive profile in VCI due to
SVD. There is a gradual transition from truly ccSVD
to cognitive complaints, cognitive impairment and
dementia, and there is a need for a treatment guideline
on VCI to fully cover this topic.
Expert consensus statement
Most group members suggest that: Considering the current
lack of evidence for cholinesterase inhibitors and memantine
in patients with ccSVD, and the small effects, at most, in
patients with VCI or vascular dementia, we advice against
prescribing these anti-dementia drugs in patients with
ccSVD to prevent or reduce cognitive decline.
All group members suggest that: There is insufficient evi-
dence for the use of any other anti-dementia drugs in
patients with ccSVD to prevent or reduce cognitive decline.
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Discussion
Small Vessel Disease is a very common condition with
substantial effects on individual subjects, their next-of
kin, and the society as a whole. SVD can have many
different clinical presentations, or can be covert
(ccSVD). After considerable discussion of the SVD
spectrum, the independent GRADE voting clearly
identified ccSVD as the priority patient group (‘P’)
for the current guideline, primarily because ccSVD is
the commonest type of SVD and a very common chal-
lenge in clinical practice. Also, there is no current
guideline on how to reduce clinical outcomes in
ccSVD for the clinician, so clinical management may
vary widely and be suboptimal and patients are con-
cerned about what they should do.
The critical outcomes (‘O’) prioritised by indepen-
dent voting of the Guideline Group to be essential to
patients and clinical services in order of importance,
were stroke, cognitive decline and dementia, dependen-
cy, mobility problems and mood disorders. In contrast,
the Guideline Group placed the outcome of progres-
sion of imaging markers of SVD as too low a priority
to include routinely in the current guideline because
clinical outcomes are crucial to patients. Also, while
imaging markers are very important as evidence of dis-
ease and often used in clinical trials, they bear an indi-
rect relationship to clinical outcomes, and do not
reflect the whole patient condition. In addition, it is
difficult to uniformly assess SVD lesions or their
change, the visible SVD features do not reflect the
full extent of brain damage, sub-visible markers of
SVD have limited acceptance, and the clinical implica-
tions of changes, such as one mL increase in WMH
volume, are of less clinical value than those of having
a stroke or receiving a diagnosis of dementia.
There are many potential interventions (‘I’), includ-
ing those licenced for use in stroke or to manage vas-
cular risk factors or other diseases but that could
potentially be repurposed, as well as lifestyle modifying
or dietary approaches. Many patients with ccSVD are
treated with vascular risk factor modifying interven-
tions, e.g. for hypertension, diabetes, or hyperlipidae-
mia, or antiplatelet therapies if they have ischaemic
cardiovascular disease. Others receive treatments for
dementias such as Alzheimer’s disease after visiting a
memory clinic. Yet the impacts on ccSVD of these
common guideline-based therapies for other conditions
are unclear. The pathophysiology of SVD remains in
debate and there may be several mechanisms of impor-
tance. The field of stroke has been dominated by dec-
ades of focus on atherosclerotic vessel occlusion,
leading to ischaemia, how to stop the block and
prevent ischaemia, so it is hardly surprising if these
concepts occupy a prominent position in the mind
when observing SVD lesions on a scan. And ‘vascular’
brain disease in memory or other non-stroke clinical
presentations may lead back to the stroke-like think-
ing. So it is understandable if the reaction on noticing
ccSVD on a brain scan is to consider aspirin treatment,
or to assume that prescribing an antihypertensive drug
will be beneficial. But are these treatments really justi-
fied, or could they be unsafe? The Guideline Group
therefore prioritised to design a common guideline
based on stroke prevention (antihypertensives, antipla-
telets, lipid lowering drugs) and lifestyle interventions
as important intervention priorities for evaluation, and
also wanted to explore the role of glucose lowering
agents (since diabetes is a major risk factor for SVD)
and conventional dementia therapies (since many
patients with SVD are seen in memory clinics).
Stroke presentations of SVD such as ‘lacunar’ stroke
or ICH, are included within current regional or nation-
al stroke guidelines85,86 and situations with clinically
clear manifestations of SVD were outside the scope
of the current guideline. Monogenic forms of SVD
were addressed recently.9 A previous guideline on
silent cerebrovascular disease only considered stroke
prevention and did not focus exclusively on ccSVD.4
A Chinese clinical practice guideline focussed on cog-
nitive impairment in cerebral SVD.145 We also refer to
current hypertension,32 diabetes,137 or dementia guide-
lines145 and white papers.156,157
We expected that there could be limited evidence on
ccSVD and clinical outcomes. Not only was the
amount of evidence limited, but the quality of evidence
was generally low reflecting primarily the small sample
sizes and methodologies including randomisation pro-
cedures. In view of our observed paucity of data, we
also considered related evidence, such as from other
likely-to-be-relevant clinical or asymptomatic popula-
tions, or effects on WMH studied with neuroimaging.
We have focused on RCTs, systematic reviews and
meta-analyses as much as possible, and include obser-
vational data only to a small extent. Even with this
approach, the quality of evidence is very limited,
although some of our recommendations are strong.
Implications for clinical practice
Hypertension is a major risk factor for SVD and for
stroke. Patients with hypertension should have their BP
well controlled, with some evidence that lower BP tar-
gets may reduce WMH progression, supporting the use
of lower suggested targets in cardiovascular disease
prevention guidelines.32 However, there was no evi-
dence to support the use of a specific antihypertensive
drug class to reduce BP, or treatment with
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antihypertensive drugs in patients with ccSVD who do
not have hypertension.
Patients with ccSVD should not be prescribed con-
ventional antiplatelet drugs (most evidence exists for
aspirin and clopidogrel), unless there is some other jus-
tifiable reason for doing so, such as ischaemic heart
disease or after TIA/minor stroke, since conventional
antiplatelet drugs do not appear to prevent stroke in
patients without a history of symptomatic vascular dis-
ease. We found no evidence that conventional antipla-
telet drugs prevent cognitive decline or dementia in
subjects with ccSVD.158 Aspirin has not been shown
to work for primary prevention of vascular disease159
and may be harmful if given long term as primary pre-
vention, especially in elderly people (where there is a
higher likelihood of ccSVD).78
We found that evidence on lipid lowering in ccSVD
and clinical outcomes is very limited, in contrast to the
considerable body of evidence on the benefits of lipid
lowering in primary and secondary prevention of vas-
cular disease,99,100,102,160 with limited evidence on
WMH progression. However, the Guideline Group
was somewhat divided on whether lipid lowering with
statins should be considered in ccSVD.
We considered lifestyle interventions such as smok-
ing cessation, exercise, dietary measures to avoid obe-
sity and ensure good intake of vegetables, nuts and
vitamins, good sleep habits, and avoidance of stress.
Smoking cessation should be a priority for many rea-
sons. We encourage aerobic exercise also for many rea-
sons including some evidence of its beneficial effects on
cognition. A healthy diet and avoidance of obesity are
also strongly encouraged although this is for general
health reasons rather than specifically because of evi-
dence of benefit in ccSVD.161
We found no evidence on specific effects of glucose
lowering regarding ccSVD; patients with type 2 diabe-
tes should be managed according to glucose and
HbA1c levels and interventions as advocated in diabe-
tes management guidelines,137 with some evidence that
good control of glucose levels may help reduce brain
atrophy although it has no observed effect on WMH
progression.
Although SVD is a common cause of cognitive
impairment and dementia, including in mixed demen-
tias, we found no evidence to support the use of con-
ventional licenced anti-dementia treatments such as
memantine or cholinesterase inhibitors in patients
with only ccSVD, or indeed in vascular cognitive
impairment.
Implications for future research
Clinical management of ccSVD is hampered by diffi-
culty recognising the atypical neurological, neuropsy-
chiatric symptoms10 and cognitive profiles11,12
Table 13. Recommendations for future trials of ccSVD.
Variables Details of variables Comments
Description of SVD MRI verified WMH, lacunes, micro-
bleeds, perivascular spaces etc
MRI is preferable
Selection of subjects No history/signs of previous stroke;
VCI or dementia with selected type
(s) of SVD from row above
Consider stratification by SVD lesion
burden and lesion type




Age, gender, ethnicity, educational level.
If possible also socioeconomic status
Vascular risk factors Smoking, hypertension, BP levels, dia-
betes mellitus, blood glucose levels,
atrial fibrillation, ischaemic heart
disease, serum lipid levels
Co-variate adjustors or minimisation
variables; also include age and ideally
educational attainment or a measure
of premorbid cognitive ability
Treatment Double blind RCT is preferable Or open label blinded outcome
Outcome measures Ischaemic or haemorrhagic stroke,
cognitive decline or dementia,
dependency, death, major adverse
cardiovascular events, mobility, or
mood disorders
Primary outcome should be clinical;
Secondary outcomes could include
other clinical outcomes, and/or
repeated MRI assessments of e.g.
structural or vascular function
measures
Observation period At least 1 year, preferably longer; may
depend on the outcome(s)
Follow-up at least every 6 months,
including safety assessment
SVD: small vessel disease; MRI: magnetic resonance imaging; WMH: white matter hyperintensities; VCI: vascular cognitive impairment; BP: blood
pressure; RCT: randomised controlled trial.
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associated with higher burden of ccSVD lesions and
likely to differentiate patients with a high risk of pro-
gression to clinical outcomes.5 Better recognition and
definition of these symptoms might help identify
patients at high risk of adverse SVD outcomes for
focused clinical trials.
Research into SVD is also still hampered by varied
terminology for SVD lesions1 and lack of agreed search
strategies that capture the range of presentations and
outcomes. Further efforts are needed to improve search
standards for research into SVD.
Although the search identified 8302 references, the
evidence-based management of ccSVD is severely ham-
pered by a lack of direct evidence with many unan-
swered questions to address in future research
(Table 13). Many large, observational cohort, other
epidemiology, or genetic studies, have documented,
beyond reasonable doubt, that common vascular dis-
orders and lifestyle factors are clearly related to ccSVD.
However, association is not causation. There are far
too few trials testing whether modifying these factors
reduces the important, debilitating, clinical effects of
ccSVD, either individually or with combined modifica-
tion approaches. The latter is important since risk fac-
tors commonly are related to each other and may have
additive or multiplicative impacts. One reason for the
limited impacts in ccSVD of e.g. BP lowering, on stroke
or cognitive or WMH progression outcomes, may be
because other risk factors remain being unaccounted
for.
The lack of benefit of aspirin in ccSVD provides
further evidence that SVD is not primarily athero-
thromboembolic, adding to evidence from genetic stud-
ies which have shown relations between WMH and
hypertension but not atheroma genes49 and that the
SVD stroke subtype was the only stroke subtype not
associated with a genetic risk score for thrombosis.162
A non-atherothromboembolic SVD pathogenesis
may appear to contradict the apparent benefit of cilos-
tazol73 and potentially of statins.21 However, cilostazol
is a weak antiplatelet drug with numerous other effects
on the endothelium and white matter163 which could
explain its apparent benefits in stroke prevention, par-
ticularly in small vessel stroke. Also, statins do not just
lower lipids but have direct endothelial and anti-
inflammatory effects which could benefit SVD. An
obvious starting point for development of better
drugs for SVD would be an exploration of these alter-
native modes of action of drugs like statins and
cilostazol.
Furthermore, it is possible that atherothrombotic
processes occur in damaged microvessels as an end
stage of SVD lesion formation. Future studies should
consider if effects of interventions differ between
patients with different severities of ccSVD and with
different proportions of WMH vs lacunes since these
lesions may have different underlying pathologies.
ccSVD is considered as ‘asymptomatic’ but in fact is
associated with subtle neurological as well as neuropsy-
chiatric and cognitive symptoms10 which are associated
with a high burden of lesions on brain imaging and
therefore a high risk of stroke, dementia and other
adverse outcomes,5 but are largely overlooked in clinics
and probably by patients themselves. Better recogni-
tion and definition of the symptoms that are associated
with ccSVD, as well as refined imaging and circulating
biomarkers for ccSVD currently under investigation,
may help identify a group of patients for ‘secondary
prevention’, with a high burden of disease and higher
risk for future adverse outcomes, who might benefit
from aspirin or equivalent drugs, and this could be
tested in clinical trials.
Numerous drugs, licenced for other purposes and
therefore with known safety profiles, are available for
testing and have relevant modes of action based on
current knowledge of causes of sporadic SVD. There
is increasing evidence that sporadic SVD is related to
endothelial dysfunction, which affects myelin and
inflammation as well as influencing brain fluid manage-
ment, and is not primarily atherothrombotic. Drugs
with multiple relevant modes of action of potential
interest for ccSVD include cilostazol, dipyridamole,
pentoxifylline, and various antihypertensive agents,
all with presumed endothelial stabilising effects, some
with myelin supporting effects, as well as statins and
other anti-inflammatory drugs.163 Novel drug targets
and therapeutic approaches that will enable specific
treatments for the pathological processes underlying
ccSVD are also needed, beyond the management of
vascular risk factors.
Several trials have evaluated different interventions
on SVD lesion progression on neuroimaging, mostly as
part of secondary outcomes in a subset of trial partic-
ipants, although most of them did not specifically
target participants with ccSVD. While we strongly
encourage future trials with clinical endpoints, collec-
tion of follow-up MRI would also be valuable to
increase information on SVD lesion change and link
this to clinical outcomes. But WMH progression is an
unstandardized, and usually biased (due to typical
losses to follow-up of at least 20%54), outcome mea-
sure that is of indirect relevance to clinical outcomes.
There are also many trials evaluating other intermedi-
ary outcomes such as forearm blood flow, or cerebral
blood flow, or diffusion tensor imaging, which are also
not a substitute for hard clinical endpoints. Nor do
such intermediary endpoint trials require smaller
sample sizes than trials with hard clinical endpoints,
since changes in WMH are typically small and fluctua-
tions in WMH can have unexpected effects on sample
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size, including requiring substantial increases in
sample.164
In contrast, there are few studies examining novel
modifiable risk factors for ccSVD. Yet it is likely that
there are many such risk factors beyond hypertension,
diabetes, and atherosclerosis, since treatment of hyper-
tension, even intensive treatment of hypertension, as
discussed in PICO1, has such a limited effect on pre-
venting SVD progression. There is a knowledge gap of
understanding how additional mechanisms contribute
to the development and deterioration of SVD. More
research in these areas is urgently needed. Genomic
and other high-throughput molecular approaches
hold the promise of accelerating the discovery of mech-
anistic pathways underlying ccSVD, by providing new
clues on biological pathways involved , with possibly
applications for drug development and drug reposition-
ing opportunities.
Trials with hard clinical endpoints targeting specifi-
cally patients with ccSVD are a priority going forward
(Table 13). These trials should be powered to detect
clinical outcomes. Analysis of epidemiological data to
provide reliable estimates of clinical endpoints with
credible confidence limits should be a priority. Since
SVD can present in several different ways, trials
should a) have broad entry criteria and b) carefully
balance the randomisation for key prognostic variables
including: SVD lesion burden; age; gender; mode of
presentation; vascular risk factors particularly hyper-
tension, smoking, diabetes; educational attainment
and/or an estimate of premorbid cognitive ability,
and possibly a measure of current socioeconomic
status. Each of these are important predictors of base-
line status and hence risk of disease progression,
making it important to ensure that the trial groups
are well balanced.
As more information about sporadic SVD mecha-
nisms emerge, it may become important to consider
trials in different SVD subtypes such as cerebral amy-
loid angiopathy, haemorrhagic forms of SVD, other
clinical SVD entities, as well as subtypes of sporadic
SVD selected for a high proportion of genetic risk
variants.
Future guidelines should assess interventions for the
common clinical presentations of SVD including lacu-
nar ischaemic stroke, other types of ischaemic and hae-
morrhagic stroke with pre-existing SVD, MCI and
dementia, mobility disorders and depression. These
were outside the scope of the current guideline but
account for a large number of persons attending
stroke services, memory clinics, mobility and psychiat-
ric clinics.
Plain language summary
Covert (without any clear clinical symptoms) Small
Vessel Disease is a common finding on brain imaging
scans, especially in people 50-55 years or older, and is
known to increase the future risk of stroke, dementia,
dependency, mobility and mood disorders. There has
been no current guideline to support the care of per-
sons found to have ccSVD on brain scanning so as to
reduce their risk of stroke, cognitive decline or demen-
tia or other physical or mental problems that may
restrict their independence. The ESO Guideline
ccSVD Group was established and used approved
methodologies to assess the current literature for evi-
dence to help reduce the risk of health problems in
persons found to have ccSVD.
We searched the literature up to December 2020 for
studies on ccSVD and treatments to prevent stroke,
cognitive decline or dementia, heart attacks, becoming
dependent on someone else, problems with walking or
mood and found a total of 8302 studies. We focused on
commonly available treatments that are already used to
prevent stroke such as aspirin, BP control, lowering the
level of fats (cholesterol) in the blood, also lifestyle such
as stopping smoking, exercise, diet including vitamins,
sleep, and medications for making sure that the blood
sugar is not too high and also for treating dementia.
We focused on randomised clinical trials since they
provide the most reliable evidence.
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We found only a small number of studies to be
about ccSVD but we used all the information that we
considered to be relevant. This showed that patients
with ccSVD should have their BP checked and if they
have a high BP then they need to have their BP care-
fully controlled according to current BP guidelines.
Unless they have a good reason, like a previous heart
attack or stroke, patients with ccSVD should not take
drugs like aspirin or clopidogrel to reduce the stickiness
of platelets in the blood since these medications may
not be beneficial for ccSVD. Patients with ccSVD can
take statin treatment even if they have no other reason
to do so since ccSVD represents a group of people with
an increased risk of vascular events such as strokes and
lipid lowering is beneficial in primary prevention of
vascular disease – this is not likely to cause much
harm and may do some good. Patients with ccSVD
should not smoke – smoking is harmful in many
ways including to the brain. They should take regular
exercise since, in addition to the general health benefits
of exercise, it may help to stop any decline in cognitive
abilities and delay the onset of dementia. A healthy diet
including plenty of green leafy vegetables, avoiding
being overweight and good sleep habits are all impor-
tant for general health. Patients with diabetes and
ccSVD should focus on keeping their blood sugar
well controlled according to current Diabetes
Guidelines. We found no reason to suggest that drugs
that are currently used to treat Alzheimer’s dementia
such as cholinergic drugs or memantine, would help
patients with ccSVD unless there was another reason
for taking these drugs.
We emphasise and strongly encourage more
research into ccSVD examining clinical outcomes that
can be observed by the patients themselves or their
relatives, and not just looking at whether the brain
looks better on a scan. There are a wide range of
other drugs that are currently licenced for other
blood vessel or brain disorders or inflammatory disor-
ders that have effects that need to be examined whether
they might help stop the development and clinical dis-
eases due to ccSVD. There is also a need for more novel
drugs targeting mechanisms of action that are now
being developed through research. All of these should
be tested in clinical trials as soon as possible.
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